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SUMMARY 1 
 
1 SUMMARY 
Platelets play a central role in thrombosis, hemostasis, and inflammation. Here, we 
show that activated platelets release inorganic polyphosphate (polyP), a polymer of 60-
100 phosphate residues that directly bound to and activated the plasma protease factor 
XII. PolyP-driven factor XII-activation triggered release of the inflammatory mediator 
bradykinin by plasma kallikrein-mediated kininogen processing. PolyP increased 
vascular permeability and induced fluid extravasation in skin microvessels of mice. 
Mice deficient in factor XII or bradykinin receptors were resistant to polyP-induced 
leakage. PolyP initiated clotting of plasma via the contact pathway. Ablation of intrinsic 
coagulation pathway proteases factor XII and factor XI protected mice from polyP-
triggered lethal pulmonary embolism. Targeting polyP with phosphatases interfered 
with procoagulant activity of activated platelets and blocked platelet-induced 
thrombosis in mice. Infusion of polyP restored defective plasma clotting of Hermansky-
Pudlak Syndrome patients, which lack platelet polyP. The data identify polyP as a new 
class of mediator having fundamental roles in platelet-driven proinflammatory and 
procoagulant disorders. 
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2 ZUSAMMENFASSUNG 
Thrombozyten spielen eine zentrale Rolle bei Thrombose, Hämostase und 
Entzündungsprozessen. Wir zeigen, dass aktivierte Thrombozyten Polyphosphate 
(polyP) mit einer Kettenlänge von 60-100 Phosphatuntereinheiten sekretieren. PolyP 
binden und aktivieren die Serinprotease Faktor XII. PolyP-induzierte Faktor XII-
Aktivierung führt über Kallikrein zur Freisetzung des Entzündungsmediators Bradykinin 
aus seinem Vorläufermolekül, dem hochmolekularen Kininogen. In einem Ödem-
Modell zeigen wir, dass polyP die Gefäßpermeabilität in der Rückenhaut von Wildtyp-
Mäusen erhöhen. Faktor XII- oder Bradykinin B2 Rezeptor-defiziente Tiere waren vor 
polyP-induzierter Ödembildung geschützt. PolyP aktivieren die intrinsische 
Blutgerinnungskaskade im Plasma. In einem polyP-vermittelten lethalen 
Lungenemboliemodell waren Faktor XII- und Faktor XI-defiziente Mäuse im Gegensatz 
zu Wildtyp Tieren geschützt. Behandlung mit Phosphatase hebt die prokoagulante 
Aktivität stimulierter Thrombozyten auf und blockiert die Plättchen-induzierte 
Thrombusbildung in Mäusen. PolyP normalisieren die verlängerte Blutgerinnungszeit 
von Hermansky-Pudlack Patienten. Die Daten zeigen, dass es sich bei polyP um eine 
neue Klasse von Mediatoren mit prokoagulanten und proinflammtorischen 
Eigenschaften handelt.  
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3 INTRODUCTION 
3.1  The contact system 
The contact system is an enzymatic cascade in the blood that is activated following 
blood contact to negatively charged surfaces. The system consists of the zymogens 
factor XII (FXII), plasmaprekallikrein (PPK) and the nonenzymatic cofactor high-
molecular weight kininogen (HK) (Cochrane and Griffin, 1982; Colman and Schmaier, 
1997). This cascade is initiated by autoactivation of FXII. Activated FXII (FXIIa) triggers 
four plasma cascade pathways such as the intrinsic pathway of coagulation, the 
fibrinolytic, the complement, and the kallikrein-kinin systems. (Fig. 1).  
 
 
Figure 1. The contact system. The contact system consists of blood coagulation factor XII (FXII), 
plasmaprekallikrein (PPK) and the nonenzymatic cofactor high-molecular weight kininogen (HK). FXII 
becomes autoactivated following contact to negatively charged surfaces, resulting in activated factor XII 
(FXIIa). FXIIa cleaves PPK to form plasmakallikrein (PK). PK enhances FXIIa formation in a positive 
feedback loop. PK cleaves HK to liberate the proinflammatory mediator bradykinin (BK). PK also activates 
the fibrinolytic system through the conversion of pro-urokinase (ProUK) to the plasminogen activator 
urokinase (UK). FXIIa initiates plasmatic blood coagulation through conversion of factor XI (FXI) to 
activated FXI (FXIa), and may initiate the complement cascade through activation of complement factor 
C1.  
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Tiny amounts of FXIIa generated by autoactivation convert PPK to active 
plasmakallikrein (PK). In an amplification loop PK activates further FXII zymogens, 
thereby amplifying the initial signal (Cochrane and Revak, 1980). PK in turn liberates 
the vasoactive proinflammatory nonapeptide bradykinin (BK) from HK (Nishikawa et al., 
1992). In addition to trigger BK formation, FXIIa also activates the fibrinolytic system 
through PK that activates pro-Urokinase (ProUK) to the plasminogen activator 
urokinase (UK) (Loza et al., 1994). PK-formed FXIIa initiates the classical pathway of 
the complement cascade in vitro via activation of the C1r and to a lesser degree the 
C1s subunits of the first component of complement system (Ghebrehiwet et al., 1981). 
Contact system-driven initiation of fibrin formation involves activation of factor XI (FXI) 
by FXIIa. This reaction triggers the intrinsic pathway of coagulation (Davie and Ratnoff, 
1964; Macfarlane, 1964; Davie et al., 1991; Gailani and Renne, 2007).  
 
3.2 Coagulation factor XII (Hageman factor) 
Human FXII (Hageman factor) is a serine-protease primarily produced by hepatocytes 
that circulates in plasma as a zymogen (Revak et al., 1974; Griffin and Cochrane, 
1976; Fujikawa and Davie, 1981). The FXII plasma concentration is ≈25-30 µg/ml 
(Revak et al., 1974; Saito et al., 1976). The zymogen comprises a polypeptide chain 
(Mw of 80 kDa) of 596 amino acid residues (Fujikawa and McMullen, 1983; McMullen 
and Fujikawa, 1985), coded by a single gene of 12 kb mapped on chromosome 5. The 
FXII gene consists of 13 introns and 14 exons (Cool and MacGillivray, 1987; Citarella 
et al., 1988). Upon activation, the zymogen is converted into a two-chain active 
protease, FXIIa. 
Activation of FXII requires two steps: (i), binding to negatively charged surfaces 
that induces a conformational change (Cochrane et al., 1973; Griffin, 1978; Samuel et 
al., 1992) and (ii), proteolytic cleavage of FXII between the amino residues Arg353-Val354 
resulting in FXIIa (α-FXIIa). The protease consists of a heavy chain (Mw of 52 kDa) and 
a light chain (Mw of 28 kDa), connected by a disulfidebond, Cys340-Cys346.  
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The C-terminal light chain contains the catalytic triad of a serine-protease 
composed of the residues Asp442, His393, and Ser554 (McRae et al., 1981). The 
enzymatically inactive N-terminal heavy chain is composed of five domains consisting 
of a type II region homologous to the collagen-binding domain in fibronectin (Fib II), an 
epidermal growth factor (EGF)-like domain (EGF I), followed by the type I homology or 
the fibrin finger in fibronectin (Fib I), and a second EGF-like domain (EGF II), preceding 
a kringle domain and a proline-rich region (Fig. 2) (Pixley et al., 1987a; Clarke et al., 
1989; Samuel et al., 1993; Citarella et al., 2000).  
 
Figure 2. Structure of blood coagulation FXII. Cleavage of the peptide bond Arg353-Val354 (red arrow 1) 
results in two-chain activated FXII (α-FXIIa). The two chains are connecetd by a disulfide-bond. Further 
proteolysis of the peptide bonds Arg343-Leu344 and Arg334-Asn335 (red arrows 2 and 3) by PK results in 
activated FXII-fragment (β-FXIIa). The catalytic triad of FXIIa consists of His393, Asp442 and Ser544 (red). 
The heavy chain, which harbours the putative cell binding region of FXII, consist of five domains. Fib II 
(violet), EGF I (green), Fib I (orange), EGF II (purple), kringle (light blue) and the proline-rich region 
(brown). The light chain (white) has the enzymatic properties of a serine protease. (Structure adapted from 
(Cool and MacGillivray, 1987)). 
 
The role of the individual domains of FXII is unknown. The heavy chain contains 
two artificial surface binding regions, one at the distal N-terminal end and another on its 
Fib I region (Pixley et al., 1987b; Clarke et al., 1989).  
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Studies using recombinant FXII deletion mutants identified a third putative binding site 
on the EGF II-like or kringle domain (Citarella et al., 1996). 
The activation of FXII to α-FXIIa that results from binding to negatively charged 
surfaces, is termed autoactivation (Wiggins and Cochrane, 1979; Miller et al., 1980; 
Silverberg et al., 1980; Dunn et al., 1982). Some evidence suggests that binding of 
Zn2+ ions to FXII results in increased susceptibility to autoactivation and stabilizes 
certain conformations in the activation reaction (Shore et al., 1987; Schousboe, 1990). 
There are four zinc binding sites in FXII. Further cleavages of the peptide bonds Arg334-
Asn335 and Arg343-Leu344 of α-FXIIa by PK separate the heavy from the light chain and 
result in activated FXII-fragment (β-FXIIa, Mw of 28 kDa), which consists of the light 
chain and nine amino acids of the C-terminal part of the FXII heavy chain (Dunn et al., 
1982; Tankersley and Finlayson, 1984). In spite of retaining proteolytic activity towards 
PPK and the first component of complement C1, β-FXIIa is unable to bind to negatively 
charged surfaces and to efficiently induce blood clotting via FXI activation (Cochrane et 
al., 1973; Revak and Cochrane, 1976; Revak et al., 1978).  
Mutations in the light chain of FXII result in defective enzymatic activity. There 
are several descriptions of inactive FXII mutants found in patients: Coagulation FXII 
(Washington DC) has a Cys571-to-Ser571 substitution, that leads to complete loss of 
procoagulant activity in vitro (Miyata et al., 1989). Dysfunctional defects of coagulation 
FXII (Locarno and Bern) are caused by the amino acid substitution Arg353-to-Pro353, that 
abolishes the PK-cleavage site (Wuillemin et al., 1991).  
The major inhibitor of α- and β-FXIIa, and PK in plasma is the C1 esterase 
inhibitor (C1Inh) (Forbes et al., 1970; Schreiber et al., 1973; de Agostini et al., 1984). 
C1Inh is a member of the serpin family, which inhibits serine proteases by irreversible 
binding to the enzymatic pocket (Davis, 1988). Other inhibitors of FXIIa comprise 
antithrombin III and plasminogen activator inhibitor-1 (PAI-1) (Pixley et al., 1985; 
Berrettini et al., 1989). 
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3.3 The kallikrein-kinin system 
The kallikrein-kinin system was first considered as a proteolytic system in plasma and 
in tissue that liberates the vasoactive, proinflammtory kinin hormones (BK, Lys-BK 
(kallidin) and their biologically active des-Arg9 metabolites) (Rocha et al., 1949). BK, a 
low-molecular weight nine amino acid nonapeptide, causes many characteristics of an 
inflammatory state, such as changes in local blood pressure, pain, vasodilatation, and 
increased microvessel permeability. There are two main pathways by which BK is 
generated: (i) the plasma, and (ii) the tissue kallikrein-kinin system. The latter involves 
tissue kallikrein (TK) (Margolius, 1998) and its substrate, low-molecular weight 
kininogen (LK) (Muller-Esterl et al., 1985). TK is secreted by various cells; tissues such 
as lung, kidney, intestine and brain produce large amounts of TK. The enzyme is 
processed intracellular from a precursor, tissueprekallikrein (TPK), to produce TK; 
cleavage of LK by TK yields a ten amino acid peptide, kallidin. A plasma 
aminopeptidase cleaves the N-terminal lysine from kallidin, forming peptide BK. The 
plasma kallikrein-kinin system involves PK and FXIIa. PK is immunologically and 
functionally distinct from TK. Although PK and TK have related functions (e.g. cleavage 
of kininogens), they have low sequence homology. TK prefers LK as a substrate but is 
capable of cleaving HK, whereas PK cleaves HK exclusively to liberate BK. The two 
forms of kininogen, HK and LK, results from alternative splicing of a single gene that 
consists of 11 exons (Kitamura et al., 1985; Takagaki et al., 1985). The kininogens, in 
general, can be divided into three regions: the heavy chain that is common to both HK 
and LK, the BK moiety, and the light chains that are unique to HK and LK, respectively. 
Domains 1 through 3 comprise kininogens heavy chain. Domain 4 is the BK region. 
Domain 5 for LK is its unique 12 amino acid long (4 kDa) light chain (Takagaki et al., 
1985). The longer light chain of HK is responsible for its procoagulant activity, which is 
dependent upon two characteristics: its ability to form noncovalent complexes with PPK 
or FXI (Mandle et al., 1976; Thompson et al., 1979; Scott and Colman, 1980), and its 
ability to interact with negatively charged surfaces (Scott and Colman, 1980; Schmaier 
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et al., 1988). HK mediates binding to negatively charged surfaces with its histidine-rich 
region in the light chain (domain 5) and through residues of domain 3. The HK binding 
sites for PPK and FXI are in its extreme C-terminal portion in domain 6 (complex 
concentrations are ≈70-90 µg/ml) (Herwald et al., 1996; Renne et al., 2002a).  
FXI and PPK are structurally related proteins sharing 58% amino acid sequence 
identity (Chung et al., 1986). The same structure is described for PPK and FXI, 
suggesting a common ancestor genic duplication event for PPK and FXI (Beaubien et 
al., 1991; McMullen et al., 1991a). The proteins have four tandem repeats in the N-
terminal portion of the molecule due to linking of the first and sixth, second and fifth, 
and third and fourth half cysteine residues present in each repeat. This arrangement 
results in four groups of 90 or 91 amino acids that are arranged in so-called apple 
domains (Chung et al., 1986; McMullen et al., 1991b). The binding regions for HK have 
been mapped to apple domains A1, A2, and A4 of PPK (Page et al., 1994; Renne et 
al., 1999), and A1, A2, and A4 of FXI (Renne et al., 2002b). During contact activation, 
PK cleaves HK at the C-terminal portion of the BK-sequence, leaving BK attached to 
the C-terminal end of the heavy chain (Mori and Nagasawa, 1981), and a subsequent 
cleavage liberates BK from the heavy chain. 
The Kinins exert their effects by specific activation of two distinct G-protein 
coupled receptors, BK type 1 receptor (B1R) and BK type 2 receptor (B2R) (Regoli and 
Barabe, 1980; Vavrek and Stewart, 1985). Non receptor bound hormones are rapidly 
metabolized by kininases I and II (Erdos and Sloane, 1962; Yang and Erdos, 1967; 
Sheikh and Kaplan, 1986). BK has a very short half-life (10-50 sec) in plasma (Decarie 
et al., 1996). Kininase II (angiotensin I converting enzyme, ACE) removes the C-
terminal dipeptide from BK or kallidin and generates biologically inactive fragments. 
Kininase I enzymes (arginine carboxypeptidases) are responsible for the generation of 
des-Arg9 BK and Lys-des-Arg9 BK. Under normal conditions the B1R receptor is not 
expressed in normal tissue but following an inflammatory insult, receptor expression is 
induced and mediates action of des-Arg9 kinins. The B2R receptor is constitutively 
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expressed and mediates acute vascular actions of BK and kallidin (Bhoola et al., 1992).  
Activation of the kallikrein-kinin system by FXIIa leads to BK release. The peptide 
hormone acts in a paracrine mode and activates adjacent G-protein coupled B2R. BK 
increases vascular leakage and evokes pain sensations via nitric oxide (NO) and 
prostacyclin (PGI2) dependent intracellular pathways in the endothelium (Busse and 
Fleming, 2003). NO, is derived from L-Arg by a constitutive Ca2+-calmodulin-dependent 
endothelial nitric oxide synthase (eNOS). NO induces smooth muscle relaxation by 
activating soluble guanylyl cyclase. This increases intracelullar concentrations of cyclic 
guanosine monophosphate (cGMP), which, in turn activates the G kinase and reduces 
the intracellular concentration of Ca2+ in smooth muscle cells and results in relaxation. 
Because PGI2 is also Ca2+ sensitive, synthesis of PGI2 by endothelial cells is, like that 
of NO, a Ca2+-dependent process (Chang et al., 1987).  
BK formation by activation of the kallikrein-kinin system is regulated by the C1Inh 
(Davis, 1988). The importance of this pathway is illustrated in vivo by observations in 
patients with hereditary angioedema (HAE). These patients experience painful swelling 
episodes. The classical forms of HAE, types I and II, are caused by mutations in the 
C1Inh gene, leading to a deficiency in C1Inh or a dysfunctional C1Inh protein 
(Nussberger et al., 2002). In contrast to HAE types I and II, HAE type III, another form 
of angioedema is characterised by normal C1Inh function and plasma concentration 
exists (Bork et al., 2000). Clinically, HAE type III patients show the same symptoms as 
those with HAE types I and II and suffer from life-threatening swelling attacks. A 
comprehensive genome-wide linkage analysis in HAE type III affected families 
identified a disease-associated haplotype in the gene of FXII. The mutation leads to 
increased enzymatic activity of FXII in patient plasma, indicating a critical role of FXII-
activity in the pathology of the disease (Cichon et al., 2006). 
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3.4 The intrinsic pathway of coagulation 
Under physiological conditions blood circulates in a closed system. Blood coagulation 
is a protective mechanism of the organism in response to vascular injury. The 
coagulation system reacts quickly to stop blood loss from a damaged vessel wall. 
Defective or excessive coagulation activity leads to an increased risk of bleeding 
(hemorrhage) or clotting (thrombosis), respectively. In all mammals, coagulation 
involves both a cellular (platelet) and a protein (coagulation factor) component. 
Coagulation is initiated almost instantly after endothelial damage, which leads to 
exposure of subendothelial proteins, most notably collagen. The initial response to an 
injured vessel wall is vasoconstriction, which slows the flow of blood. Circulating 
platelets rapidly bind to collagen with collagen-specific glycoprotein Ia/IIa receptors and 
aggregate to form a hemostatic thrombus at the subendothelium. Platelet adhesion is 
strengthened by von Willebrand factor (vWF), which forms links between the platelet 
glycoproteins Ib/IX/V and collagen fibrils. Activated platelets release the contents of 
stored granules, such as ADP, serotonin, platelet-activating factor (PAF), vWF, platelet 
factor 4 (PF4) and thromboxane A2 (TXA2), which in turn activates additional platelets. 
This process mechanically impedes blood loss from the wound and is called primary 
hemostasis. The platelet plug may embolize from the vessel wall and must be 
stabilized by a fibrin meshwork, which is simultaneously generated by the secondary 
hemostatic system. Plasmatic coagulation proceeds through a series of sequential 
reactions involving activation of plasma coagulation proteins (Table 1). These events 
culminate in generation of the key coagulation enzyme thrombin, which converts 
fibrinogen into fibrin. Transglutaminase factor XIII (FXIII) forms intermolecular γ-
glutamyl-ε-lysine cross-links between fibrin fibers, thereby stabilizing the clot and 
conferring resistance to proteolysis (Takahashi et al., 1986).  
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Table 1 : Plasma coagulation proteins. 
factor synonym plasma level [µg/ml] 
MW 
[kDa] function source 
I fibrinogen 3000 340 structural hepatocytes 
II prothrombin* 100 72 protease zymogen hepatocytes 
III tissue factor - 37 cofactor/initiator tissue 
IV calcium - - - plasma 
V proaccelerin 10 330 cofactor precursor hepatocyte 
VII proconvertin* 0.5 55 protease zymogen hepatocyte 
VIII antihemophilic factor 0.1 330 cofactor precursor hepatocyte 
IX christmas factor* 5 55 protease zymogen hepatocyte 
X stuart-prower factor* 10 55 protease zymogen hepatocyte 
XI thromboplastin antecedent 5 160 protease zymogen hepatocyte 
XII hageman factor 30 80 protease zymogen hepatocyte 
XIII fibrin-stabilizing factor 30 320 protrans-glutaminase hepatocyte 
PPK plasmaprekallikrein 40 85 protease zymogen hepatocyte 
HK high-molecular weight kininogen 80 120 cofactor/activation hepatocyte 
vWF von Willebrand factor 10 >220 adhesion, carrier protein endothelium 
*Vitamin K-dependent protein containing γ-carboxyglutamic acid. Data was compiled from: (Davie 
and Fujikawa, 1975; Furie and Furie, 1988). 
 
The classical cascade or waterfall model of coagulation, described in 1964 
independently by Macfarlane (Macfarlane, 1964) and Davie and Ratnoff (Davie and 
Ratnoff, 1964), consists of two converging enzymatic pathways, initiated either by 
exposure of blood to a damaged vessel wall (extrinsic pathway) or by blood-borne 
components of the vascular system (intrinsic pathway) (Fig. 3). The common final steps 
of the coagulation cascade can be divided into three reactions: activation of factor X 
(FX), formation of thrombin (FIIa) from prothrombin (FII), and cleavage of fibrinogen to 
fibrin to form the insoluble platelet-rich clot. This classic model of coagulation provides 
the conceptual framework for the clotting assays used in the clinical laboratory, the 
prothrombin time (PT) and the activated partial thromboplastin time (aPTT), which 
assess extrinsic or intrinsic pathway-mediated coagulation, respectively.  
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Figure 3. Coagulation cascade. Coagulation comprises the intrinsic (left, blue) and the extrinsic (right, 
orange) pathway. The extrinsic pathway is initiated after vascular injury by binding of cell exposed tissue 
factor (TF) to factor VII (FVII). Binding to negatively charged surfaces converts FXII of the intrinsic pathway 
to FXIIa. FXIIa then cleaves FXI to form FXIa. Factor Xa (FXa), generated by FVIIa-TF or the tenase 
complex, binds to factor V (FV). FXa-FVa (prothrombinase) complex converts prothrombin (FII) to thrombin 
(FIIa). FIIa enhances the activation of FV, factor VIII (FVIII) and FXI. During hemostasis, the tissue factor 
pathway is inactivated by platelet released tissue factor pathway inhibitor (TFPI). 
 
The extrinsic pathway is initiated at the site of injury by the exposure of tissue factor 
(TF). TF is normally not found at high concentrations in blood, but is present on cell 
membranes in subendothelial layers of blood vessel. TF is exposed to activated factor 
VII (FVIIa) when the endothelium is injured and forms a FVIIa-TF complex (Weiss et 
al., 1989; Wilcox et al., 1989). The intrinsic pathway of coagulation is initiated by FXII, 
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in a reaction involving HK and PK. This process triggers FXIIa-mediated activation of 
FXI and in the presence of Ca2+ formation of activated factor IX (FIXa). FIXa assembles 
with its cofactor activated factor VIII (FVIIIa) on a phospholipid surface and forms the 
tenase complex (FIXa-FVIIIa). The extrinsic and intrinsic pathways converge in FX 
activation. Activated FX (FXa) activates FII to generate picomolar amounts of FIIa. In 
the presence of Ca2+ FXa and the co-factor Va (FVa) form the prothrombinase complex 
(FXa-FVa), the key enzyme complex for FIIa generation. FIIa subsequently converts 
fibrinogen to fibrin by cleavage of two peptide bonds, thereby releasing two small 
peptides, fibrinopeptide A and fibrinopeptide B (Furie and Furie, 1992; Dahlback, 2000; 
Davie and Kulman, 2006). FIIa may accelerate its own formation by activation of the 
cofactors factor V (FV) and factor VIII (FVIII). Platelet released tissue factor pathway 
inhibitor (TFPI) rapidly inhibits the FVIIa-TF complex, and immediate turndowns of the 
extrinsic pathway (Broze, 1992). As a result sustained FIIa generation is dependent on 
FIXa-FVIIIa and FXa-FVa complexes. FIIa activates FXI, which is an alternative way to 
generate FIXa (Butenas et al., 2003; Walsh, 2003).  
Vitamin K is an essential cofactor for the post-translational γ-carboxylation of 
glutamate residues. The vitamin K-dependent proteins include the coagulation proteins 
FII, FVII, FIX, and FX and the anticoagulation proteins, protein S, protein C and protein 
Z. Thus the coagulation proteins share the requirement for the γ-carboxylation of the 
glutamic acid residues in order to bind Ca2+. Ca2+ ions bind active clotting factors to 
membrane surfaces. The coagulation proteins contain an N-terminal module with 9-12 
γ-carboxyglutamic acid (Gla) residues, followed by EGF-like regions. (Stenflo, 1991; 
Stenflo et al., 2000). EGF-like domains are involved in protein-protein interaction. The 
coagulation proteins FII, FVII, FIX, FX and protein C have two EGF-like domains, 
whereas protein S and protein Z have four EGF-like modules in tandem, respectively. 
Upon Ca2+ binding to the Gla residues the clotting factors are able to interact with 
biological membranes.  
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Several control mechanisms for the coagulation cascade exist because 
excessive clotting may be life threatening. These mechanisms include inactivation of 
procoagulant enzymes, fibrinolysis, and clearance of activated clotting factors (Furie 
and Furie, 1988). Plasma protease inhibitors (antithrombin III, tissue factor pathway 
inhibitor [TFPI], α2-macroglobulin, heparin cofactor II) inactivate coagulation enzymes. 
Antithrombin targets FIIa, FIXa, FXa, FXIa and FXIIa. TFPI limits the action of FVIIa-
TF. During wound healing, the fibrin clot in the vessel is degraded by plasmin, a serine 
protease generated from the plasma zymogen plasminogen. This reaction is catalyzed 
by several plasminogen activators, including tissue plasminogen activator (t-PA) and 
plasminogen urokinase activator (UK). Their activity is in turn regulated the plasma 
protease inhibitors, plasminogen activator inhibitor and α2-antiplasmin (Colman and 
Schmaier, 1986). 
Congenital deficiency in FXII (Hageman trait) is an autosomal recessive trait, first 
discovered in 1955 in the patient named John Hageman (Ratnoff and Margolius, 1955). 
Deficiency in FXII and also in the contact system proteins PPK and HK severely 
prolongs the aPTT. However, in sharp contrast to deficiency in the extrinsic factors TF 
(Bugge et al., 1996) and FVII (Rosen et al., 1997), individuals with severe deficiencies 
in any of the contact factors do not suffer from spontaneous or injury-related bleeding 
disorders (Ratnoff and Margolius, 1955; Colman et al., 1975; Sollo and Saleem, 1985). 
PK, HK, and FXII deficient patients can undergo surgical procedures without additional 
need of transfusions and clearly have a completely normal hemostatic capacity. This 
observation led to the current model that contact activation plays no role in hemostasis 
and that fibrin formation at a site of injury is exclusively initiated via the extrinsic 
pathway. However, FXII-deficient mice were found to have a profound defect in 
formation and stabilization of thrombi and suppressed BK levels, suggesting an 
important role for FXII in thrombus formation and inflammation (Renne et al., 2005a; 
Iwaki and Castellino, 2006; Kleinschnitz et al., 2006).  
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One third to one half of individuals with FXI deficiency have a mild bleeding 
diathesis, also referred to as hemophilia C (Bolton-Maggs, 2000). The FXI-related 
bleeding dysfunction can be explained by the ability of FIIa to activate FXI, which is 
considered to be an important feedback mechanism to maintain production following 
inactivation of the TF pathway by TFPI (Gailani and Broze, 1991). It is not clear if FXIa 
functions to increase the total amount of FIIa at the injured site, or act to generate FIXa 
at strategic locations within the clot. Furthermore, continued FIIa generation through 
this pathway can protect the clot from lysis by activation of thrombin activatable 
firbinolysis inhibitor (TAFI) (Von dem Borne et al., 1997). The antifibrinolytic effect of 
TAFI in FIIa-mediated FXI activation may explain the bleeding pattern in FXI-deficient 
patients (Asakai et al., 1991). 
 
3.5 Activation of coagulation factor XII 
FXII is activated in vitro by a variety of polyanionic surfaces, such as kaolin, glass, 
ellagic acid, certain polymers, nucleotides, sulfatides, misfolded proteins, and some 
types of collagen or glycosaminoglycans (Cochrane and Griffin, 1982; Maas et al., 
2008; Muller and Renne, 2008; van der Meijden et al., 2009). Activation of FXII by non-
physiological material like kaolin (a negatively charged silica) provides the basis for the 
aPTT clinical clotting assay, which is widely used to assess the integrity of the intrinsic 
pathway of coagulation and to monitor anticoagulation with heparin. Surface-
independent mechanisms for FXII activation may also contribute. Microbial enzymes 
can activate FXII by direct proteolysis (Kaminishi et al., 1994), and lung damage in 
Salmonella pneumonia has been linked to activation of contact proteases and BK 
generation (Persson et al., 2000). Protease-driven activation of FXII may also occur on 
vessel walls, where FXII and HK bind to similar sites on the endothelium (Reddigari et 
al., 1993). Although the mechanism of activating the contact system in particular FXII is 
well characterized, the nature of physiological activators in vivo has remained 
unknown.  
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Figure 4. Inorganic polyphosphate (polyP). Number 
(n) of [PO3-] residues may vary from tens to many 
hundreds depending on the cellular location and the 
metabolic state. 
Extracellular RNA, which activates FXII (Cochrane and Griffin, 1982) and is liberated 
from disintegrating cells, is prothrombotic but does not contribute to hemostatic 
mechanisms (Kannemeier et al., 2007). These findings challenge the importance of 
RNA as FXII activator in vivo. A previous study identified activation of FXII by misfolded 
protein aggregates, which specifically led to activation of the kallikrein-kinin system 
without inducing the intrinsic pathway of coagulation (Maas et al., 2008). Given that 
FXIIa activates the contact system, triggering initiation of the kallikrein-kinin system as 
well as the intrinsic pathway of coagulation, more studies are necessary to elucidate 
specific activation mechanisms of FXIIa-driven intrinsic blood coagulation and BK 
formation. For more than 40 years platelets have been linked to the intrinsic pathway of 
coagulation (Castaldi et al., 1965; Nossel et al., 1969), with platelet activation 
promoting fibrin formation in a FXII-dependent manner (Walsh and Griffin, 1981). 
These findings suggest that FXII is activated on procoagulant platelets but the 
mechanisms involved are unclear (Furie and Furie, 2008).  
 
3.6 Polyphosphate 
Inorganic polyphosphate (polyP) (Fig. 4) is a linear, unbranched polymer of tens to 
hundreds of orthophosphate (Pi) residues linked by high-energy phosphoanhydride 
bonds similar to ATP (Kornberg, 1999; Rao et al., 2009).  
 
 
PolyP is highly conserved, from archaea, bacteria, fungi, plants, insects, to mammals 
(Kulaev, 1975; Kulaev, 1979; Wood and Clark, 1988). PolyP was first found in yeast by 
Liebemann (1888). Almost 100 years ago they were observed as metachromatically 
stained „volutin granules“ in microbes (Robinson and Wood, 1986).  
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Several yeras later these volutin granules were shown to be polyP and subsequently 
found to be abundant in every cell in nature. Maintenance of intracellular phosphate 
concentrations is essential for cellular metabolism and growth. In periods of phosphate 
surplus, accumulation of polyP are stored as granules (Ogawa et al., 2000). Storage 
pools of polyP are present as osmotically inert aggregates associated with multivalent 
cations. Conversely, polyP reserves can be readily hydrolyzed to provide phosphate in 
periods of phosphate limitation by polyP degrading enzymes (Kornberg, 1999). PolyP 
may act as a substitute for ATP in various kinase reactions. PolyP kinase of E.coli 
catalyzes the reactions of transfer of energy-bond phosphate residues from ATP to 
polyP and from polyP to ADP. PolyP kinase can use polyP as a donor in place of ATP, 
thereby converting GDP and other nucleoside diphosphates to nucleoside 
triphosphates (Kulaev and Kulakovskaya, 2000). It has become apparent that polyP 
has other functions than acting as a phosphate storage polymer (Kornberg, 1999).  
Until now polyP was studied mainly in prokaryotes. Recently it has been described 
to be important for diverse basic metabolisms, for some structural functions and, for 
stress responses (Brown and Kornberg, 2004, 2008; Rao et al., 2009). In human 
platelets polyP has been identified in the dense granules by staining with 4’,6-
diamidino-2-phenylindole (DAPI) (Ruiz et al., 2004). The granules are rich in Ca2+ and 
resemble acidocalcisomes, which are widely distributed from procaryotic to eukaryotic 
cells. They are responsible for the flux of Ca2+ into the cytosol. 
A previous study demonstrated that synthetic polyP is a potent modulator of 
plasma clotting, affecting the intrinsic pathway, the fibrinolytic system, FV activation, 
and the fibrin structure (Smith et al., 2006; Smith and Morrissey, 2008b). These recent 
findings strongly indicate an important relevance of polyP for platelet-triggered 
reactions reactions in vivo.  
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3.7 Aim of the study 
FXII and the contact system proteins have experienced a revival in the last years. The 
contact system proteins are well characterized, however, the activating physiological 
surface of this system in vivo remains unknown. Human platelets contain large 
amounts of polyP, accumulated in storage organelles named dense granules. Synthetic 
polyP has a procoagulant effect, which is exerted at several levels in the blood clotting 
and fibrinolytic system. PolyP accelerates blood coagulation by activating the contact 
system and by promoting FV activation, which in turn abrogates the anticoagulant 
function of TFPI (Smith et al., 2006). Furthermore, polyP modulates fibrin clot structure, 
resulting in thicker fibrin fibers that are more resistant to fibrinolysis (Smith and 
Morrissey, 2008b).  
The aim of this study was to demonstrate, whether platelet derived polyP is the long 
sought physiological surface that activates coagulation FXII and the contact system in 
vitro and in vivo. 
The goals of the presented work can be divided into following parts: 
I) Analysis of platelet activation leading to dense granule secretion. 
II) Extraction, identification and detection of polyP from platelet released material. 
III) Investigation of polyP functions to trigger FXII-mediated BK formation in vitro 
and in vivo 
IV) Analysis of polyP-driven FXII-dependent thrombin and fibrin formation in vitro 
and in genetically altered mice. 
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4 MATERIAL AND METHODS 
4.1 Material 
4.1.1 Chemicals 
ADP       Sigma (Steinheim, Germany)  
bovine serum albumin (BSA)  Pierce (Rockford, IL, USA)  
enhanced chemoluminiscence (ECL)  MoBiTec (Göttingen, Germany)  
detection substrate 
Dowex 50Wx8    Serva, Heidelberg, Germany  
fetal bovine serum (FBS)    PAN (Aidenbach, Germany)  
fibrilar penicillin/streptomycin   PAN (Aidenbach, Germany)  
PolyP20, polyP70 and polyP1000 were kindly provided by BK Giulini (Ludwigshafen, 
Germany). All other chemicals were obtained from Sigma (Steinheim, Germany) or 
Roth (Karlsruhe, Germany). 
 
4.1.2 Enzymes, Antibodies, Proteins, Substrates, Inhibitors and Markers 
ENZYMES 
benzonase     Roche (Penzberg, Germany) 
chondroitinase ABC    Roche (Penzberg, Germany) 
proteinase K     Quiagen (Hilden, Germany) 
phosphatase, alkaline   Fluka (Taufenkirchen, Germany) 
from calf intestinal mucosa 
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ANTIBODIES 
Antibodies were from the indicated sources and used at given concentrations in 
Western Blot (WB):  
 
Horseradish peroxidase-conjugated secondary antibodies were from Dianova 
(Hamburg, Germany) (WB: 1:5,000), fluorescence-conjugated antibodies (Alexa-fluor 
488, 594, or 647, IF: 1:500) from Molecular Probes (Karlsruhe, Germany). 
PROTEINS, SUBSTRATES AND INHIBITORS 
bradykinin Sigma (Steinheim, Germany) 
collagen (Horn) type I    Nycomed (Munich, Germany)  
human FXII   American Diagnostics (Greenwich, USA)  
human fibrinogen     Sigma (Steinheim, Germany) 
icatibant     Sigma (Steinheim, Germany) 
PCK (H-D-Pro-Phe-Arg-chloromethylketone)  Bachem (Weil a. Rhein, Germany) 
Trap6 (H-Ser-Phe-Leu-Leu-Arg-Asn-OH)  Bachem (Weil a. Rhein, Germany) 
thrombin  Roche Diagnostics (Mannheim, Germany) 
human plasmin  Sigma (Steinheim, Germany) 
S-2302, S-2238  Chromogenix (Milano, Italy) 
PROTEIN MARKER, DNA LADDER 
Prestained Protein Ladder   Fermentas (St.Leon-Rot, Germany) 
Low molecular weight DNA ladder  NEB (Frankfurt a.M., Germany) 
Antibody Source/Class Concentration Supplier/Reference 
α-HKL12 mAb (mouse) 1/2000 (Henderson et al., 1994) 
α-FXI 199 pAb (rabbit) 1/200 (Renne et al., 2002a) 
α-FXII pAb (goat) 1/2000 Nordic Labs (Tilburg, Netherlands) 
α-Fibrin mAb (mouse) 1/500 (Hui et al., 1983) 
α-Fibrinogen pAb (goat) 1/200 Santa Cruz (Heidelberg; Germany) 
α-GAPDH mAb (mouse) 1/8000 Chemicon (Billerica, USA) 
α-MBK3 pAb (rabbit) 1/250 (Haasemann et al., 1991) 
α-P2 mAb (mouse) 1/1.000 (Renne et al., 2002) 
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4.1.3 Eukaryotic Cells 
EA.hy926 cells, human umbilical vein endothelial cells (HUVEC, Cambrex Bioproducts) 
and ECV304 cells were cultivated and passaged according to ATCC 
recommendations. 
 
4.1.4 Patients 
Citrated human plasma was collected from healthy volunteers (University Hospital 
Würzburg, Germany). In some experiments pooled normal plasma and FXII deficient 
plasma were from George King Bio-Medical (Overland Park, Kansas, USA). Patients 
with Hermansky-Pudlak syndrome type 1 were enrolled in a protocol approved by the 
National Human Genome Research Institute’s Institutional Review Board, and gave 
written, informed consent. 
 
4.1.5 Animals 
Animal studies were approved by the “Bezirksregierung of Unterfranken”. FXII-/-, FXI-/-, 
C1Inh-/-, and B2R-/- mice backcrossed for >10 generations to C57Bl/6 background were 
described previously (Borkowski et al., 1995; Gailani et al., 1997; Pauer et al., 2004). 
We used 6- to 8-week old animals and employed age- and sex-matched wild-type mice 
(C57Bl/6) from Charles River (Sulzfeld, Germany). 
 
4.2 Methods 
4.2.1 Cell culture  
EA.hy926 cells and human umbilical vein endothelial cells (HUVEC, Cambrex 
Bioproducts) of passages 2-5 were cultivated as described (Profirovic et al., 2005; 
Renne et al., 2005). Cells were grown in a 5 % CO2 saturated atmosphere at 37°C, and 
passaged according to ATCC recommendations. Cells were grown to confluence and 
subcultured using trypsination solution containing 0.05 % Trypsin/EDTA after removing 
growth medium and washing with PBS.  
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ECV304 cells were grown in Dulbecco´s modified Eagle´s medium (DMEM) containing 
4.5 g/l glucose, 1 mM sodium pyruvate, and 10% FBS and penicillin/strepomycin 
solution (100 U/0.1 mg/ml). Cells were grown to confluency in 14 cm-plastic petridishes 
in the recommended medium. After trypsination cells were harvested by centrifugation 
at 1,000x g for 5 min, washed several times with PBS and used for extraction of polyP.  
 
4.2.2 Cell freezing and thawing 
Cells were washed with PBS, trypsinated, pelleted (200x g, 5 min) and counted. The 
pellet was resuspended in freezing medium (20 % FBS, 100 U/0.1 mg/ml 
penicillin/streptomycin, 10 % DMSO in DMEM high glucose) at a final concentration of 
1x106/ml, aliquoted into 1.8 ml cryotubes. The aliqouts were stored over night at -80°C 
and then transferred in liquid N2. 
 
Frozen cells were thawed by warming the vials in a 37°C water-bath and immediately 
transferring them into 15 ml tubes with 10 ml growth medium. Cells were pelleted by 
centrifugation, medium was removed, and cells were resuspended in fresh growth 
medium and seeded in a small dish T-75. 
 
4.2.3 Blood sampling (mouse) 
Adult mice were anaesthesized, and blood from retroorbital veins was taken into tubes 
containing 1/10 of citrate. With this method a maximum of 1 ml blood (1/10 of body 
weight) can be taken per mouse. The animal survives and blood can be taken again 
one week later. Blood was centrifuged at 1,800 rpm for 5 min. Supernatant was taken 
and centrifuged at 800 rpm for 7-8 min at RT to obtain platelet rich plasma (PRP). 
Following centrifugation at 2,500 rpm for 10 min obtained platelet poor plasma (PPP). 
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4.2.4 Platelet isolation (mouse) 
Mice were bled under anesthesia. Blood was collected into a tube containing citrate 
buffer and centrifuged at 1800 rpm for 5 min. Supernatant (plasma with platelets and a 
few erythrocytes) was taken and centrifuged at 800 rpm for 7-8 min at RT to obtain 
platelet rich plasma (PRP). (In addition an optional „quickrun“ could be done with 
remaining plasma and supernatants combined.) To wash platelets, PRP was 
centrifuged at 2,800 rpm for 5 min in the presence of prostaglandin (PGE1) (1 µM) and 
the pellet was resuspended in New Tyrode’s buffer (145 mM NaCl, 0.5 mM NaH2PO4, 
5 mM KCl, 1 mM MgSO4, 5 mM D-Glucose, 10 mM HEPES, 2 mM CaCl2, 0.35 % BSA, 
pH 6.5) containing PGE1 (1 µM) incubated for 5 min in a 37°C water bath. After a 
second centrifugation step, platelets were resuspended in the same buffer and 
incubated at 37°C for additional 5 min. Platelets were finally centrifuged as above, 
resuspended in Tyrode’s buffer (pH 7.4) and left to incubate for 30 min at 37°C before 
analysis. 
 
4.2.5 Platelet and cell count 
Platelet or cell suspension were diluted 1/10 in PBS (10 mM Tris pH 7.5, 150 mM 
NaCl) and counted with the Coulter haematological cell counter as instructed by the 
manufacturer.  
 
4.2.6 Extraction of polyP 
EA.hy926, ECV304 and HUVEC cells were seeded at a density of 108 cells/cm2 in 
14 cm plastic dishes and extraction of polyP was performed as described (Kumble and 
Kornberg, 1995). The washed cells were suspended in 500 µl of lysis buffer (50 mM 
Tris pH 7.5, 1 M urea, 0.1 %SDS, 10 mM EDTA) and sonicated in an ice-bath for three 
10 sec bursts with 30 sec cooling intervals using a Polytron (Brinkmann Instruments).  
For extraction of polyP from activated platelets, platelets were isolated from 
thrombocyte concentrate of healthy volunteers.  
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Platelets were harvested by centrifugation at 750x g for 15 min at room temperature, 
and the platelet pellet was resuspended in New Tyrode’s buffer (pH 6.5) and PGE1 
(1 µM). The platelets were centrifuged and washed one more time. The final platelet 
pellet was resuspended in New Tyrode's buffer (pH 7.4) at a final concentration of 
7.5x1011 platelets/ml. After one hour of rest in a 37°C water bath, washed platelets 
were used for experiments. Platelets were activated with thrombin (2 U/ml), Trap6 
(0.2 mM), collagen (0.2 mg/ml) for 1 min, as well as with ADP (0.1 mM) for 5 min. All 
steps were performed at 37°C in a water bath. After activation platelets were pelleted 
by centrifugation at 2,700x g for 15 min. Supernatant containing platelet released 
material was collected for isolating polyP. As a control, supernatant from untreated 
platelets was collected.  
The supernatants from activated or control platelets and cell lysates were incubated 
with proteinase K (750 µg/ml) at 37°C for 2 h. Proteins were removed by extraction with 
an equal volume of phenol/chloroform (1:1, w/v equilibrated with Tris-HCl, pH 7.5); the 
phases were separated by centrifugation at 14,000x g for 10 min. The aqueous phase 
was transferred to another tube and further purified. The phenol layer was 
backextracted with 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, shaken vigorously and 
centrifuged at 14,000x g for 10 min. The pooled aqueous phases were then extracted 
with an equal volume of chloroform. The polyP were precipitated with barium acetate at 
a final concentration of 0.1 M at pH 4.5 at 4°C for 4 h, rotating overhead. The polyP 
precipitate was collected by centrifugation at 14,000x g for 30 min, resuspended in 
water and solubilized by the addition of few beads of ion-exchange resin Dowex 50Wx8 
in NH4+ form (SERVA Electrophoresis, Heidelberg, Germany). The mixture was 
incubated by shaking for 10 min at RT, followed by centrifugation at 10,000x g for 
30 min. The supernatant was first treated with benzonase (350 µg/ml) in 5 mM MgCl2 
after shaking 1 h at 37°C. Afterwards chondroitinase ABC (5 U) was added and 
incubated for 5 h at 37°C, pH 8. Contaminating proteins in the sample were removed 
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by phenol/chloroform and chloroform extraction as described above. The polyP was 
concentrated under vacuum and analyzed. 
 
4.2.7 Analytical urea-PAGE of extracted polyP 
Extracted polyP were determined by electrophoresis on 7 M urea/5 % polyacrylamide 
gels in 1xTBE (890 mM Tris, 890 mM H3BO4, 20 mM Na2EDTA). The gels were pre-run 
at 300 V for 1 h. PolyP were mixed with 1/4 volume 5x TBE-sample buffer (50 % 
Sucrose, 450 mM TBE pH 8.3, 13.5 mM Na2EDTA, 0.2 % BPB), and loaded on the gel. 
Electrophoresis was performed at 300 V until the dye reached half of the gel. PolyP 
was detected by staining with 0.05 % toluidinblue- or DAPI solution consisting of 25 % 
methanol, and 5 % glycerol and destaining in 25 % methanol and 5 % glycerol. PolyP 
of defined chain lengths (polyP125 and polyP1000) were run in parallel. 
 
4.2.8 Toluidine blue staining of polyP 
Electrophoresed polyphosphates were analyzed according to a method of Smith (Smith 
and Morrissey, 2007). Gels were stained by agitation for 15 min in fixative solution 
(0.05 % toluidin blue, 25 %MetOH, 5 %Glycerol) destained by three changes of 
destaining solution (25 %MetOH, 5 % Glycerol) over 3 h, and imaged with white light 
on a flatbed scanner. 
 
4.2.9 DAPI staining of polyP  
Gels were agitated for 30 min at room temperature in DAPI fixative solution (2 mg/ml 
DAPI, 1 mg/ml p-phenylenediamine, 10 mM EDTA pH 8.0, 25 % MetOH, 5 % Glycerol) 
using foil-covered containers to avoid exposure to ambient light. The gels were then 
destained in two 1 h changes of fixative (1 mg/ml p-phenylenediamine, 10 mM EDTA 
pH 8.0, 25 % MetOH, 5 % Glycerol) in foil-covered containers. Gels illuminated with 
365 nm light on a UV transilluminator (ChemiImager 5500, Alpha Innotech) were 
documented. 
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4.2.10 Analytical agarose-gel and positive staining of polyP  
PolyP were separated on 1.5 % agarose gel prepared using TBE (90 mM Tris, 90 mM 
Boric Acid, 10 mM EDTA pH 8.3) as electrophoresis buffer and stained with 0.1 % 
toluidine blue (Gomes et al., 2008). Alternatively, 20 µg/ml DAPI, and 1 mg/ml p-
phenylenediamine in 1xTBE were used. Photographs of gels illuminated with 365 nm 
light on a UV transilluminator were taken (ChemiImager 5500, Alpha Innotech). 
 
4.2.11 NMR-analysis  
A sample of commercial polyP125 (25 mg) (Sigma-Aldrich) and a sample of lyophylized 
lysate (10 mg) were dissolved in heavy water (D2O) and the 31P NMR spectra recorded 
at 202.4 MHz and 25°C using a Bruker Avance 500 NMR spectrometer. Pulse delay 
and repetiton time were set at 0.03 and 100 sec, respectively, to ensure correct signal 
integration. The content of the various species was then calculated directly from the 
signal intensities. 
 
4.2.12 SDS-polyacrylamid gel electrophoresis (PAGE) and western blot 
Tris/Glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed using 8 % or 10 % (w/v) polyacrylamide separating gels.  
 
 Stacking gel Separating gel 
 4 % 8 % 10 % 
Acrylamide/Bisacrylamide 
30 %/0.8 % (w/v) 29:1 
0.83 ml 2.7 ml 3.3 ml 
1 M Tris pH 6.8 0.63 ml - - 
1.5 M Tris pH 8.8  2.5 ml 2.5 ml 
10 %SDS 0.05 ml 0.1 ml 0.1 ml 
10 % ammonium persulfate 0.05 ml 0.1 ml 0.1 ml 
TEMED 0.005 ml 0.006 ml 0.004 ml 
Total volume 5 ml 10 ml 10 ml 
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Plasma samples were diluted in 2x Laemmli sample buffer (1.25 mM Tris pH 6.8, 10 % 
ß-mercaptoethanol, 0.02 % BPB, 4 % SDS, 20 % Glycerin) and loaded the wells. The 
starting current of the gel was 80 V and increased to 150 V after samples reached the 
separation gel (electrophoresis buffer: 25 mM Tris pH 8.9, 192 mM Glycerin, 0.1 % 
(w/v) SDS). A semi-dry system was used to transfer the proteins from the gel to the 
nitrocellulose membrane (150 mM for 2 h at RT, transfer buffer: 25 mM Tris pH 8.9, 
192 mM Glycin, 20 % (v/v) Methanol).  
To verify the transfer, the nitrocellulose was stained with Ponceau S. For blocking of 
nonspecific binding sites the membrane was incubated in 5 % non-fat dry milk in PBS-
Tween 0.05 % (PBS-T) for 1 h, followed by incubation with diluted primary antibody in 
3 % non-fat dry milk in PBS-T for 2 h at RT or overnight at 4°C. Horse-radish 
peroxidase-labelled secondary antibody was freshly diluted in 5 % non-fat dry-milk in 
PBS-T and incubated with the membrane for 1 h at RT. After primary and secondary 
antibody incubation membranes were washed several times with PBS-T. 
Protein detection was performed using an enhanced chemiluminescence detection kit, 
X-ray films and a Kodak developer machine.  
 
4.2.13 Detection of contact phase proteins  
Plasma samples (0.2 µl plasma/lane) were separated on SDS-PAGE gels, under 
reducing conditions and electrotransferred to a nitrocellulose membrane. Contact 
phase proteins were probed using antibodies against bradykinin (MBK3), plasma 
kallikrein (P2), FXII, and FXI (AS199), respectively, as well as horseradish peroxidase-
conjugated secondary antibodies, followed by a chemiluminescence detection method 
as described above. 
 
4.2.14 Measurement of thrombin generation 
Thrombin generation was measured according to the method of Aronson with minor 
modifications as previously described (Aoki et al., 1997) using the chromogenic 
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substrate S-2238. The change in optical density was recorded spectrophotometrically 
at 405 nm for 40 min at 37°C by a Bio-Kinetics Reader (Biotek Instruments Inc., 
Friedrichshall, Germany). Thrombin generation in real time was analyzed by the 
calibrated automated thrombography (CAT) method as described by Hemker et al. 
(Hemker et al., 2006), in a Fluoroscan Ascent fluorometer (Thermo Scientific) equipped 
with a dispenser, according to the manufacturer`s instruction (Thrombinsocope BV, 
Maastricht, The Netherlands). All experiments were run in duplicate for 60 min and 
thrombin generation was calculated using the Thrombinoscope software package 
(Version 3.0.0.29).  
 
4.2.15 Contact phase system activation assay 
Human citrate plasma (PPP) was supplemented with increasing concentrations of 
polyphosphate (0.5-1000 µg/ml in 75 mM Tris pH 7.4, 10 mM ZnCl2). Samples were 
incubated for 45 min in a 37°C water bath. The reaction was stopped by the addition of 
reducing 2x Laemmli sample buffer containing 4 % SDS. Following electrotransfer, 
nitrocellulose membranes were probed with HKL-12 antibody (1:2,000), anti-FXII 
(1:500), anti-FXI (1:250) or the anti-PK antibody PK2 (0.5 mg/ml) and horseradish 
peroxidase-coupled secondary antibody (1:5,000, DAKO, Hamburg, Germany). 
 
4.2.16 Activation of the intrinsic pathway in vitro 
Human citrate-anticoagulated plasma was incubated with polyP (0.5 – 1000 µg/ml) for 
30 min at 37°C. The reaction was stopped by the addition of reducing 2x Laemmli 
buffer containing 4 % (w/v) SDS. 0.2 µl plasma per lane were analyzed by western 
blotting as described (Renne et al., 2005). BK plasma concentrations were quantified 
with MARKIT-M-Bradykinin ELISA (Dainippon Pharmaceutical, Osaka, Japan). 
Activation of purified FXII (200 nM) by kallikrein (0.5 nM) was analyzed by incubating at 
37°C in the presence of either dextran sulfate (1 µg/ml), polyP125 (5 µg/ml) or buffer 
alone (20 mM Hepes pH 7.4, 100 mM NaCl; HBS).  
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Reactions were stopped at various times (0 – 60 min) in HBS buffer containing 
polybrene (5.5 µg/ml) and soy trypsin inhibitor (100 µg/ml). Activity was quantified 
using a chromogenic substrate for FXIIa (200 nM, Bachem, USA) and read against a 
standard curve of purified FXIIa for 60 min at 405 nm in a VERSAmax microplate 
reader (Molecular Devices). Autoactivation of FXII (200 nM) was analyzed in a similar 
manner with addition of surfaces but in the absence of kallikrein. 
 
4.2.17 Coagulation assays in plasma 
PolyP- and kaolin-triggered clotting was assessed using a “Kugelkoagulometer” (KC10; 
Amelung). 100 µl of citrated human plasma was incubated with buffer or with polyP or 
kaolin (100 µg/ml) for 120 sec at 37°C before addition of CaCl2, after which the time to 
clot formation was recorded. For determination of recalcification clotting times, citrated 
platelet-rich plasma was supplemented with Ca2+ ionophore A23187 (5 µM) or Trap6 
(30 µM) at 37°C for 10 min in the presence or absence of alkaline phosphatase (from 
bovine intestinal mucosa, 10 U/ml) before addition of CaCl2. Activation of FXII by polyP 
was analyzed as described (Renne et al., 2005a), using the chromogenic substrate  
S-2302 (2 mM) and a Bio-Kinetics Reader (BioTek Instruments Inc.) at 37°C. Human 
platelets were isolated from whole blood of consenting healthy individuals and from 
patients with Hermansky-Pudlak Syndrome (HPS). Isolated platelets were stimulated 
for 20 min at 37°C with Trap6 (50 µM) and collagen (10 µg/ml). Clotting assays were 
performed in a Start 4 coagulometer (Diagnostica Stago) with pooled normal plasma 
with addition of either normal or HPS platelets (1.5 x1010) in the presence and absence 
of additional polyP125 (10 µg/ml). Clotting was monitored in pooled normal plasma and 
FXII deficient plasma over a range of polyP concentrations (0 – 650 µg/ml), using a 
microplate turbidity assay as previously described. Results are expressed as the mean 
time to reach half-maximal turbidity. 
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4.2.18 Determination of FXII activation by polyP 
Activation of FXII by polyP was carried out in a 96-well microtiter plate. The amount of 
FXIIa formed in human citrate plasma was determined from the rate of hydrolysis of the 
chromogenic substrate S-2302 (2 mM), and the increase in absorbance at 405 nm was 
recorded at time intervals of 1 min for a period of 60 min by a Bio-Kinetics Reader 
(BioTek Instruments Inc., Friedrichshall, Germany) set at 37°C.  
 
4.2.19 PolyP-induced pulmonary thromboembolism 
Mice were anesthetized by i.p. injection of 2,2,2-tribromoethanol and 2-methyl-2-
butanol (0.15 ml/10 g of body weight from a 2.5 % solution), and polyP (300 µg/g body 
weight in NaCl) was slowly injected into the inferior vena cava. Alternatively Trap6 
(0.7 µg/g body weight) was infused. In some experiments mice were injected i.v. with 
phosphatase (15 U/g body weight) before the challenge. Animals still alive after 30 min 
were considered survivors. 
 
4.2.20 Histopathologic analysis 
Mice were sacrificed, and lungs were rapidly removed and fixed at 4°C in buffered 4 % 
paraformaldehyd, pH 7.4. Tissues were dehydrated and embedded in paraffin (Histolab 
Products AB), cut into 8 µm sections, and stained with Mayer’s hematoxylin and eosin. 
 
4.2.21 Detection of fibrin deposition 
Lung tissue was placed in buffer (0.05 M Tris, 0.15 M NaCl, 500 U/ml heparin, final 
pH 7.6) on ice and homogenized (Brinkmann Instruments, Inc., Westbury, NY, USA). 
Plasmin digestion was performed by a modification of the method of Francis (Francis et 
al., 1980). Human plasmin (0.32 U/ml) was added to the tissue homogenate, followed 
by agitation at 37°C for 6 h. More plasmin (0.32 U/ml) was then added, and samples 
were agitated for additional 2 h, then the mixture was centrifuged at 2,300x g for 15 min 
and the supernatant was aspirated.  
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Samples of plasmin-treated lung homogenates (400 mg) were boiled in reducing SDS 
sample buffer for 5 min and subjected to SDS-PAGE (10 %; reduced). The amount of 
fibrin ß-chains normalized to identical lung tissue weight was determined by western 
blot, using the fibrin-specific mAb59D8 antibody (Hui et al., 1983).  
 
4.2.22 Skin vascular leakage assay 
Animals were backcrossed for more than 8 generations to C57BL/6J background and 
their wild-type littermates were used as controls. All experiments and animal care were 
approved by the “Regierung of Unterfranken“. Five- to seven-week-old male mice were 
employed for the leakage models. Mice were anesthetized with a single i.p. injection of 
ketamine/xylazine (80 mg/kg ketamine and 10 mg/kg xylazine), and a total of 200 µl of 
sterile-filtered 0.25 % Evans blue dissolved in sterile saline (0.9 % NaCl) was injected 
intravenously in the retroorbital plexus. 10 min later, 50 µl of bradykinin (100 µM) or 
saline was injected intradermally in the dorsal region, using a tuberculin syringe. The 
animals were killed 10 min after the intradermal injections by decapitation.  
The skin was removed, mounted, and photographed. Skin samples were removed by 
using a circular template, and the Evans blue dye was extracted by incubation in N,N 
dimethylformamide overnight at 55°C. The following day, the Evans blue fluorescence 
from individual skin samples was quantified spectrophotometrically at an excitation 
wavelenght of 620 nm and an emission wavelenght of 680 nm. The concentration of 
Evans blue was normalized by dividing with the value corresponding to skin samples 
injected with saline. 
 
4.2.23 PolyP binding assays  
Purified human FXII, FXI, PK, HK, antithrombin (AT) or albumin (10 µg) were incubated 
for 10 min with increasing concentrations of polyP125 (0 – 100 µg) before being mixed 
with sample buffer (60 mM Tris-HCl pH 6.8, 10 % glycerol, 0.01 % bromophenol blue).  
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Samples were resolved on pre-cast 10 % Tris-glycine gels (Invitrogen) under native 
conditions and were stained for protein with Gelcode Blue (Pierce) according to the 
manufacturer’s instructions. PolyP was immobilized onto porous zirconia beads 
essentially as described (Lorenz et al., 1994). Briefly, 250 mg zirconia beads were 
incubated with 10 mg/ml polyP125 in water for 20 h at 37˚C. The beads were then 
washed thoroughly with distilled water before blocking unreacted sites with 10 % BSA 
for 15 h at ambient temperature. After washing in distilled water the prepared zirconia 
beads were dried in a vacuum oven at 80˚C for 2 h. Control beads were treated with 
water and BSA only. PolyP-zirconia beads (10 mg dry weight) were washed with 
binding buffer (200 µl; 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 % BSA) twice before 
addition of proteins (5 µg). After incubation at ambient temperature for 30 min the 
mixtures were centrifuged in mini-spin columns at 1,677x g for 30 sec. The flow-
through was collected and the polyP-zirconia beads were washed first with binding 
buffer (200 µl) followed by elution buffer (200 µl; 50 mM Tris-HCl pH 7.5, 1 M NaCl, 
0.1 % BSA). Recovery of proteins from the beads at the various stages was analyzed 
by Western blot with specific antibodies. 
 
4.2.24 Data analysis 
All experiments were performed at least in triplicate and data shown are means ± SD. 
Data were analyzed using one-way analysis of variance (ANOVA) with Dunnett`s post 
test. P values <0.05 were considered statistical significant. 
 
RESULTS 33 
 
5 RESULTS 
5.1 Activated platelets release polyP 
Platelet dense granules contain polyP (Ruiz et al., 2004). We analyzed whether 
activated/procoagulant platelets release polyP. Washed human platelets were 
stimulated with ADP (0.1 mM), thrombin receptor-activating peptide 6 (Trap6, 0.2 mM), 
collagen (0.2 mg/ml), or thrombin (2 U/ml) and polyP was isolated from stimulated 
platelet supernatants using an ion-exchanger based method, which has been 
previously used to purify polyP from cell lysates (Kumble and Kornberg, 1995); it was 
then separated by agarose-gel electrophoresis and probed for polyP with toluidine blue 
(Fig. 5A) and a more sensitive DAPI-based fluorescent stain (Fig. 5B) (Smith and 
Morrissey, 2007). Incubation of polyP extracted from thrombin-stimulated platelets with 
proteinase, RNase, DNase, or glycosaminoglycan-cleaving enzymes did not alter the 
staining patterns (not shown). In contrast, treatment with phosphatase (Psp, 0.05 U/µg 
polyP), which hydrolyzes polyP, completely abolished the signals (Fig. 5A and B, 
“thrombin+Psp”). Platelet polyP migrated similarly to synthetic polyP with mean chain 
lengths of 70 ± 16 (polyP70) phosphate units, and at higher mass compared to 
polymers of 20 ± 6 phosphates (polyP20). 
PolyP is not unique to platelets. In this regard we isolated the polyanions from 
EA.hy926, ECV304, and HUVEC endothelial cells. Examination of purified samples by 
urea-PAGE analysis, followed toluidine blue and DAPI staining procedures, shows the 
presence of polyP in all three cell lines (Fig. 5C, D). To confirm identity of the extracted 
material as polyP we treated cell lysates with phosphatase (Psp, 0.05 U/µg polyP for 
12 h). 
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Figure 5. (A and B) Activated platelets secrete long-chain polyP. Washed platelets (3.8x1013 platelets 
each) were stimulated with ADP (0.1 mM), Trap6 (0.2 mM), collagen (0.2 mg/ml), thrombin (2 U/ml), or 
buffer (“w/o”) and polyP was isolated from the supernatants. PolyP were separated by agarose gel 
electrophoresis and stained with toluidine blue (A) or DAPI (B). Synthetic polyP with mean chain lengths of 
20 (polyP20), 70 (polyP70) or 125 (polyP125) phosphate units in lanes 1-3 as size standards. The purified 
material from thrombin-stimulated platelets was incubated with phosphatase (0.05 U/µg polyP; “thrombin + 
Psp”) prior to electrophoresis. Negatively charged chondroitin sulfate (CS) confirmed specificity of staining. 
A bp DNA ladder as size standard is indicated on the left. (C and D) Urea-PAGE analyses of endothelial 
cell-derived polyP. PolyP were isolated from lysed EA.hy926, ECV304, and HUVEC endothelial cells, 
treated with buffer or phosphatase (0.05 U/µg polyP; lane labelled as “Psp”), and separated by urea-
PAGE. Synthetic polyP of 125 (polyP125) and 1000 (polyP1000) mean chain lengths were loaded as size 
standards. PolyP was stained with toluidine blue (C) or DAPI (D). Since we used a polyacrylamid gel, we 
loaded a protein marker as weight standard on the left. 
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We determined the chain length of platelet polyP, using 31P-NMR. The relative ratios of 
signal intensities of the phosphate end groups (∝-P, -10.2 ppm) versus central 
phosphates (ß-P, -22.1 ppm) yielded a mean chain length of platelet polyP of 80, 
consistent with its migration in the agarose matrix (Fig. 6A). Our NMR analysis 
indicated that the mean chain length of “polyP75” used in previous studies (Ruiz et al., 
2004; Smith et al., 2006) is 125 (Fig. 6B). Integration of all 31P signals revealed that P 
content of total platelet released inorganic phosphates was 5 % monophosphate, 13 % 
diphosphate, 10 % cyclotriphosphate, 3 % ADP, and 69 % polyP.  
 
 
 
Figure 6. (A and B) 31P NMR spectrum of platelet polyP and synthetic polyP125 at 202.4 MHz. (A) The 
terminal and internal phosphates of the polyP chain give signals at 10.2 (doublet, blue arrow) and 22.1 
(red arrow) ppm, respectively; ratios of their intensities yielded a mean chain length of 80 for platelet 
polyP. Other phosphate species present are monophosphate (0.0 ppm, 5 %), diphosphate (-10.4 ppm, 
13 %), cyclotriphosphate (-21.4 ppm, 10 %) and ADP (-11.2 ppm, 3 %). (B) Terminal and internal 
phosphates of the polyP chain give signals at 9.6 and 21.8 ppm, respectively. From the ratios of signal 
intensities of terminal and internal phosphates, the mean chain length of synthetic “polyP75” was 
determined to be 125. The other major signals arise from the presence of monophosphate (0.0 ppm, 
9.0 %), diphosphate (-10.2 ppm, 11.5 %), cyclotriphosphate (-21.6 ppm, 7.0 %) and cyclotetraphosphate (-
23.8 ppm, 2.3 %). 
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5.2 PolyP activates the contact system in vitro 
FXII is activated by binding to polyanions (Cochrane and Griffin, 1982). We tested 
platelet polyP for FXII activation, using the chromogenic substrate S-2302, which is 
hydrolyzed by active FXII (FXIIa) (Fig. 7A). Addition of polyP (100 µg/ml) to platelet-
free plasma (PFP) initiated FXIIa generation with similar kinetics and potency as an 
identical concentration of kaolin. Kaolin is one of the most potent contact activators and 
is used in diagnostic clotting assays (Colman, 2006). Treatment of polyP with 
phosphatase (0.05 U/µg polyP) before addition to plasma reduced polyP-driven FXIIa 
generation in a time-dependent manner. Digestion for >60 min completely abolished 
the FXIIa-generating activity of polyP (Fig. 7A), suggesting that a minimal length of 
polyP is necessary for inducing FXII activation. Indeed, synthetic polyP of mean chain 
length ≤45 phosphate units failed to trigger FXII activation in plasma, whereas polyP, 
that exceeded a threshold mean chain length of 65 phosphate subunits, readily initiated 
FXIIa formation (Fig. 7B). To discriminate between polyP-mediated FXII autoactivation 
and FXII activation by kallikrein (which is generated from plasma prekallikrein (PK) by 
FXIIa) (Tankersley and Finlayson, 1984), we incubated purified FXII and activated PK 
with polyP. PolyP was as efficient a surface as dextran sulfate (a strong contact 
activator (Samuel et al., 1992)) in supporting kallikrein-driven activation of FXII 
(Fig. 7C). When autoactivation of FXII was investigated without the addition of 
activated PK to the reaction, polyP generated significant amounts of FXIIa compared to 
the no surface control, but was not as efficient as dextran sulfate (Fig. 7D).  
 
 
Figure 7. PolyP triggers contact activation of factor XII. (see next page) (A) FXIIa formation was 
quantified by hydrolysis of the chromogenic substrate S-2302 at 405 nm in human plasma samples 
incubated with 100 µg/ml polyP ( ) or kaolin (). Platelet polyP was either untreated (0’) or pretreated 
with phosphatase (0.05 U/µg polyP) for 10 ( ), 30 ( ), or 60 min ( ). Data are means ± SD, n=5. (B) 
FXIIa activity. Human plasma was incubated with buffer, kaolin, or polyP of 3, 25, 45, 65, 125 or 1000 
chain length (100 µg/ml each). Plasma FXIIa activity was quantified after 20 min by absorbance of the 
chromogenic substrate S-2302 at 405 nm. Shown are means ± SD, n=8. (C and D) Plasma-free activation 
of purified FXII (200 nM) was analyzed in the presence (C) or absence (D) of PK (0.5 nM). The mixture 
was stimulated with dextran sulfate (; 1 µg/ml), polyP ( ; 5 µg/ml), or buffer (). FXIIa concentrations 
were determined following S-2302 hydrolysis. Data are means ± SD, n=4. 
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The ability of a molecule to act as a surface for contact activation relies on interactions 
of contact factors with the negatively charged surface (Colman, 1984). A gel shift assay 
demonstrated direct binding of polyP to contact system factors (Fig. 8A). 
Electrophoretic mobility shifts indicated strong interaction of polyP with both FXII or HK, 
whereas binding to PK and FXI was weaker. PolyP did not bind to antithrombin (AT) or 
albumin (ALB). Zirconia beads coated with either polyP or BSA confirmed specific and 
direct polyP binding to FXII, PK, HK, and FXI, with FXII being the strongest polyP-
interacting protein (Fig. 8B).  
 
 
 
Figure 8. (A) Gel-mobility shift analyses of polyP binding to proteins. Purified FXII, FXI, PK, HK, 
antithrombin (AT) or albumin (ALB) were incubated with buffer (“w/o“) or with increasing concentrations of 
polyP125 (0 – 100 µg) for 10 min, after which mixtures were resolved on a 10 % Tris-Glycine gel under 
native conditions and stained for protein using Gel Code Blue. (B) Protein binding to immobilized polyP. 
PolyP (left) or albumin (ALB, right) were coupled to zirconia (zirconium dioxide) beads. FXII, FXI, PK, or 
HK (5 µg each) were incubated with the beads, after which the flow-through (“FT”) fraction was collected 
by centrifugation using mini spin columns. The beads were washed with a low salt buffer (50 mM NaCl; 
“LS”) followed by a high salt buffer (1 M NaCl; “HS”). Fractions were probed by Western blotting with 
appropriate antibodies. Starting material (“SM”) refers to the initial protein load added to the beads. These 
data resulted from collaboration and were kindly provided by Dr. N. Mutch. 
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5.3 PolyP triggers bradykinin generation in plasma 
FXIIa initiates BK release by PK-mediated cleavage of HK (Fig. 9A). We examined 
contact activation and BK release in human plasma and found that polyP at 
concentrations ≥1 µg/ml initiated complete HK cleavage (Fig. 9B). Consistently, BK 
concentrations were high (>750 ng/ml) in these samples, but low in samples treated 
with buffer (31 ± 4 ng/ml) or with ≤1 µg/ml polyP, which was not sufficient to initiate HK 
processing (Fig. 9C). To confirm that the FXII/PK cascade mediated BK generation 
from HK, we probed for the protease zymogens by Western blotting and found that 
polyP ≥1 µg/ml triggered complete PK and partial FXII activation with a slightly higher 
concentration (≥2 µg/ml) results in complete activation of plasma FXII (Fig. 9B). 
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Figure 9. PolyP activates the kallikrein-kinin system. (A) Scheme of polyP-induced FXII-mediated HK-
cleavage and release of BK. (B) PolyP-induced cleavage of FXII, PK and HK in plasma. Human plasma 
was incubated with increasing concentrations of polyP (0.5 – 1000 µg/ml) or buffer control (“w/o”), and 
then subjected to SDS-PAGE and western blotting. Samples were probed with antibodies against FXII, 
HK, and PK. (C) PolyP-induced bradykinin release in plasma. BK in polyP-incubated samples was 
quantified by ELISA. The columns give mean values ± SD, n=4.  
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5.4 PolyP increased vascular permeability by a bradykinin-dependent 
mechanism 
A hallmark of BK activity is increase in vascular permeability (Han et al., 2002; 
Nussberger et al., 2002). To analyze whether polyP initiates contact system-mediated 
capillary leakage via BK formation, we employed a Miles edema model (Miles and 
Miles, 1952) in genetically altered mice (Fig. 10A-F). Injected stimuli (50 µl each) 
triggered dermal vessel leakage, which was visualized by Evans Blue tracer. 
Extravasated tracer was extracted from the tissue, quantified by fluorescence emission, 
and plotted relative to the NaCl-induced signal in wild-type (WT) mice (set to 1.0) 
(Donelan et al., 2006). In WT mice, platelet polyP or synthetic polyP125 (10 µg each) 
initiated leakage, that was increased 7.9 ± 0.8 and 7.4 ± 1.0 fold, respectively, higher 
than vehicle alone, respectively (n=10, Fig. 10A and G). BK (100 µM) stimulation in WT 
mice increased leakage 11.3 ± 1.5 fold of vehicle (n=10, Fig. 10A). To confirm that 
polyP induces vascular leakage by releasing BK, we employed B2R-deficient (B2R-/-) 
mice, which are resistant to BK signaling (Borkowski et al., 1995) and protected from 
BK-driven edema formation (Han et al., 2002). B2R-/- mice were mostly resistant to 
polyP-induced increase in permeability (polyP 1.1 ± 0.2 and polyP125 1.1 ± 0.1, 10 µg 
each, n=5, Fig. 10B and G). Similarly, BK failed to induce a response in B2R-/- mice 
(1.1 ± 0.2, n=5, not depicted) whereas injection of histamine (100 µM) resulted in 
considerable leakage (7.7 ± 1.3, Fig. 10B), confirming that B2R-/- mice are susceptible 
for edema formation by contact system independent pathways. Because FXII-
independent mechanisms for PK activation exist (Schmaier and McCrae, 2007), we 
analyzed polyP-triggered leakage in FXII-deficient mice (FXII-/-), which are defective in 
contact system-driven BK formation (Iwaki and Castellino, 2006; Pauer et al., 2004). 
FXII-/- mice were almost completely resistant to polyP-induced leakage, and the degree 
of edema was not significantly different from the buffer-treated group (polyP 1.3 ± 0.2 
and polyP125 1.2 ± 0.2, n=10, Fig. 10C and G). BK-stimulated edema formation in FXII-/- 
mice was similar to that observed in WT animals (10.4 ± 1.3, n=10, Fig. 10C).  
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Hereditary angioedema is characterized by recurrent attacks of swelling owing to a 
deficiency of a functional C1 esterase inhibitor (C1INH), which is the major plasma 
inhibitor for several complement proteases, FXIIa and PK (Zuraw and Herschbach, 
2000). In C1INH-defective individuals, poorly defined stimuli trigger contact system-
driven excess of BK, that causes attacks of edema (Davis, 2006). PolyP initiated 
excessive edema in C1INH null animals, that exceeded levels in WT by >40% (polyP 
11.8 ± 0.9 and polyP125 10.9 ± 0.8, n=10, Fig. 10D and G), whereas injection of BK-
induced (11.0 ± 0.8, Fig. 10D) tracer extravasation was similar to WT mice levels 
(11.3 ± 1.5, n=10, Fig. 10A). 
Since congenital deficiency in B2R or FXII protects mice from polyP-driven edema 
formation, pharmacological targeting of BK-signaling or -formation should provide 
similar protection. To address this hypothesis, we treated WT mice with an FXIIa 
inhibitor H-D-Pro-Phe-Arg-chloromethylketone (PCK, 8 mg/kg body weight) 
(Kleinschnitz et al., 2006), or with the selective B2R antagonist icatibant (Icat, 
175 µg/kg body weight) 5 min prior to polyP application. PolyP was unable to induce 
leakage and edema formation in WT mice pretreated with PCK (polyP 1.9 ± 0.4 and 
polyP125 1.2 ± 0.2, n=10, Fig. 10E and G) or Icat (polyP 1.6 ± 0.2, polyP125 1.1 ± 0.2, 
n=10, Fig. 10F and G). BK function was blocked by Icat (Fig. 10F), but was 
independent of FXII activity (1.2 ± 0.1, n=10, Fig. 10E). Inhibitor application after polyP 
injection did not significantly reduce edema formation (not shown). Together, these 
findings in loss- and gain-of-function models are consistent with the in vitro findings and 
indicate that polyP activates FXII-driven BK formation in vivo. 
 
Figure 10. PolyP triggers contact system-mediated bradykinin-induced edema in mice. (see next 
page) (A-F) Evans blue was intravenously infused as a tracer into the following: (A) WT mice, (B) B2R-/-
mice, (C) FXII-/-mice, (D) C1INH-/- mice, (E) PCK-infused WT mice (8 mg/kg body weight), and (F) 
icatibant-administered WT mice (175 µg/kg body weight). Dorsal skin edema formation was induced by 
intradermal injection of 50 µl saline (NaCl), BK (100 µM), platelet polyP (10 µg), or synthetic polyP125 
(10 µg), respectively, and visualized by tracer extravasation after 30 min. (B2R-/- animals were treated with 
100 µM histamine instead of BK). (G) Evans blue tracer from skin welts was extracted and quantified. 
Extravasated tracer is plotted as fold-increase of saline-induced signal in WT mice to control for inter-
animal variability. Data are means ± SD of 10 independent experiments. 
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5.5 PolyP initiates the intrinsic pathway of coagulation in plasma  
FXIIa initiates fibrin formation by the intrinsic pathway of coagulation (Gailani and 
Renne, 2007). To analyze the procoagulant activity of polyP we incubated human 
plasma with increasing concentrations of polyP (0.5 – 1000 µg/ml) and followed 
generation of FXIIa and activation of its principal substrate in the intrinsic pathway of 
coagulation, FXI, by Western blotting (Fig. 11A); we also quantified thrombin 
generation (Fig. 11B). PolyP ≥1 µg/ml triggered the conversion of FXII and FXI to the 
active proteases as indicated by the disappearance of the zymogen forms at 80 kDa 
(Renne et al., 2002a) (Fig. 11A). FXIIa/FXIa formation correlated with polyP-triggered 
thrombin generation (Fig. 11B). Digestion of polyP with phosphatase (0.05 U/µg polyP) 
impeded the procoagulant activity of the polymer. Furthermore, we compared polyP 
with kaolin for initiating thrombin formation in plasma in real time, using a fluorogenic 
thrombin substrate (Hemker et al., 2006). PolyP and kaolin (100 µg/ml each) driven 
thrombin generation had almost identical kinetics (lag time = time to achieve 10 nM 
thrombin of 6.6 ± 0.1 for polyP vs. 6.3 ± 0.2 min for kaolin and time to maximal 
thrombin/peak 13.1 ± 0.3 vs. 13.8 ± 0.2 min), potency (peak = maximal thrombin of 
142.9 ± 5.2 vs. 144.8 ± 1.1 nM), and effects on total thrombin generation (endogenous 
thrombin potential (ETP) = integrated thrombin generation over 60 min of 2700 ± 97 
and 2682 ± 34 nM*min, n=5 each) (Fig. 11C). Pre-incubation of polyP with 
phosphatase (0.05 U/µg polyP) largely abolished thrombin formation stimulated by 
polyP (ETP <100 nM*min). We assessed the procoagulant activity of polyP by in vitro 
clotting tests. 
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Figure 11. PolyP activates the intrinsic pathway of coagulation in plasma. (A) PolyP-induced 
cleavage of FXII and FXI in plasma. Plasma was incubated for 30 min at 37°C with increasing 
concentrations of polyP (0.5 – 1000 µg/ml) and analyzed for zymogen forms of FXII and FXI by Western 
blotting. Untreated plasma (“w/o”) shows initial FXII and FXI levels. (B) Thrombin generation in plasma 
incubated with buffer alone ( ), 100 µg/ml kaolin (), or platelet polyP ( ; “polyP”), synthetic polyP75 ( ), 
platelet polyP treated with phosphatase prior to addition of plasma ( ; “polyP+Psp”). Data are means ± 
SD, n=5. (C) Comparison of thrombin-forming activities of polyP and kaolin. Clotting was initiated by 
addition of 100 µg/ml polyP or kaolin to plasma. Thrombin generation was monitored in real time by using 
a fluorogenic substrate for thrombin and analyzed using Thrombinoscope software. Lag time is the time to 
achieve 10 nM thrombin; peak indicates the maximal thrombin concentration; time to peak is the time to 
achieve maximal thrombin starting from addition of the stimulus, and ETP is endogenous thrombin 
potential (integrated thrombin generation over 60 min). Data are means ± SD, n=5. PolyP and kaolin-
stimulated coagulation parameters do not differ significantly using Student’s t test. 
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We assessed the procoagulant activity of polyP by in vitro clotting tests. Addition of 
polyP (0 – 5 µg/ml) to normal plasma, but not to FXII-depleted plasma shortened the 
clotting time in a dose-dependent manner (Fig. 12A). Clotting times in recalcified 
plasma triggered by synthetic polyP125, and polyP1000 were similar to kaolin (139 ± 16 
and 77 ± 2 vs. 69 ± 14 sec in PFP, and 52 ± 16, and 87 ± 156 vs. 51 ± 14 sec in PRP), 
whereas polyP3 stimulated clotting did not significantly differ from buffer control 
(833 ± 43 vs. 957 ± 58 sec in PFP, and 743 ± 31 sec vs. 813 ± 57 in PRP, P>0.05, 
n=5) (Fig. 12B). These findings demonstrate a similarity in the mechanism of polyP and 
kaolin-driven clotting and strongly suggest that polyP contributes to fibrin formation 
predominantly via activation of the intrinsic pathway of coagulation. 
 
 
 
Figure 12. Plasma clotting times. (A) PolyP was added to normal plasma () or FXII-immunodepleted 
plasma ( ) at a range of concentrations (0 - 5 µg/ml) with clot formation quantified as the half-maximal 
change in turbidity at 405 nm. Data are means ± SD, n=3. These data resulted from a collaboration and 
were kindly provided by Dr. N. Mutch. (B) Recalcification clotting times were determined in human platelet-
free plasma (PFP) and platelet-rich plasma (PRP) incubated with 100 µg/ml polyP3, polyP125, or polyP1000, 
respectively, for 1 min prior to CaCl2 addition. Data are means ± SD, n=5. 
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5.6 Deficiencies in intrinsic pathway proteases protect mice from polyP-
induced pulmonary embolism 
To analyze polyP for fibrin formation in vivo we challenged WT and FXII-/- mice in a 
model of lethal pulmonary thromboembolism (PE) by intravenous infusion of polyP 
(300 µg/g body weight). All WT mice with the exception of a single animal (14/15) died 
within 5 min after polyP application (Fig. 13A). In contrast, FXII-/- mice were significantly 
protected from polyP-induced PE, with 12 out of 15 FXII-/- mice surviving the challenge 
for >30 min (**P<0.01 FXII-/- vs. WT). To show that the high level of survivors observed 
in FXII-/- mice was a direct result of defective polyP-driven FXII activation rather than a 
secondary effect associated with hereditary FXII deficiency, we reconstituted FXII null 
mice with human FXII (hFXII) (2 µg/g body weight). Intravenous infusion of human 
protein corrected the prolonged aPTT clotting time of FXII-deficient murine plasma to 
normal values (28 ± 4 sec) and restored susceptibility for lethal pulmonary embolism 
after polyP infusion, with 12 out of 15 reconstituted animals dying (Fig. 13A). This 
supports the critical role of polyP-driven FXII activation in this model. Pretreatment of 
polyP with phosphatase (0.05 U/µg polyP) abolished its procoagulant activity, with 
14/15 mice surviving infusion of degraded polyP (Fig. 13B). The infestin4-based 
recombinant FXIIa-inhibitor CSL829 (Schmidbauer, 2009) and PCK irreversibly inhibit 
the amidolytic activity of FXIIa and PK-mediated activation of FXII. CSL829 (150 µg/ml) 
blocked polyP-driven FXII and consecutive FXI, PK and HK activation steps in plasma 
(Fig. 13C). To test the protective potential of FXIIa-inhibitors for polyP-driven 
thrombosis, WT mice were intravenously injected with CSL829 (15 µg/g body weight) 
10 min prior to polyP infusion, which prolonged the aPTT (48 ± 9 sec) and significantly 
protected mice from lethal PE (12 out of 15 survived; **P<0.01 vs. WT, Fig. 13A). PCK 
(8 µg/g body weight) provided similar protection from polyP-triggered thromboembolism 
(12/15 survived, not shown). Histologic sections of lung tissue from polyP treated mice 
and counting of formed thrombi are shown in Figure 13D and E.  
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While the majority of vessels are obstructed in WT and hFXII-reconstituted FXII-/- mice 
(dead and survivors), virtually no thrombi were found in FXII-/- mice and in WT animals 
treated with FXIIa-inhibitors. Some interstitial edema were observed in WT and 
reconstituted FXII-/-, but not in FXII-/- or inhibitor treated mice, indicating that thrombosis 
was associated with increased permeability in these animals. If the prothrombotic effect 
of polyP is mediated by the intrinsic pathway in vivo, FXI-/- mice (deficient in the primary 
FXIIa substrate in the intrinsic pathway of coagulation) should be protected from 
pulmonary embolism similarly to FXII-/- animals (Fig. 13A). Indeed, FXI deficiency 
conferred resistance to polyP-induced PE and FXI null mice were largely protected 
from polyP challenge (11/15 survived; **P<0.01 FXI-/- vs. WT). Targeting B2R was 
shown to confer protection from arterial occlusion induced by vascular injury (Shariat-
Madar et al., 2006). We analyzed B2R-/- mice in our PE model and found that almost all 
(13/15) animals died (Fig. 13A), suggesting that BK did not contribute to polyP initiated 
PE. To confirm that polyP-initiated FXII activity contributes to pathological thrombosis 
by the intrinsic pathway of coagulation, we measured fibrin formation in lung tissues by 
quantitative immunoblot analysis of urea-insoluble tissue extracts. We used the 
antibody 59D8 (Hui et al., 1983), which recognizes a neo-epitope exposed on fibrin, 
following thrombin-dependent cleavage of fibrinogen and does not cross-react with the 
precursor protein. Fibrin accumulation was significantly reduced in the lungs of FXII-/- 
and inhibitor treated mice, compared to WT and reconstituted animals (Fig. 13F). 
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Figure 13. PolyP triggers thrombosis in vivo. (A and B) Survival times following i.v. polyP challenge. 
(A) Pulmonary thromboembolism was induced by i.v. infusion of platelet polyP (300 µg/g body weight) in 
WT mice, FXII-/- mice, FXII-/- mice reconstituted with human FXII (“hFXII”, 2 µg/g body weight), WT mice 
infused with FXII inhibitor CSL829 (150 µg/g body weight), FXI-/- mice, or B2R-/- mice. Mortality was 
assessed in each group (n=15); animals still alive 30 min after challenge were considered survivors. 
Asterisks indicate significant reduced mortality in FXII-/-, CSL829-treated WT, and FXI-/- animals as 
compared to WT (P<0.05). (B) PolyP was phosphatase digested (0.05 U/µg polyP) prior to infusion into 
WT animals and survival was analyzed as in panel A. (C) Efficacy of CSL829 inhibitor. Plasma 
supplemented with CSL829 (150 µg/µl) or buffer (“w/o”) was incubated with polyP (500 µg/ml) for 30 min, 
and analyzed for zymogen FXII, FXI, PK and HK by Western blotting. (D) Hematoxylin and eosin stained 
sections of lungs of WT, FXII-/-, CSL829 infused WT, and hFXII reconstituted FXII-/- mice 30 min after 
polyP administration (bar = 100 µm). (E) Thrombi per visual field were counted at 10x magnification from 
sections such as those in panel D. Data are mean ± SD for 100 fields. (F) Accumulation of fibrin in lung 
tissue of polyP treated WT, FXII-/-, CSL829 pretreated WT, and reconstituted FXII-/- mice. Fibrin formation 
30 min after polyP challenge was analyzed by western blotting. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) served as loading control. 
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5.7 PolyP initiates fibrin formation on activated platelets 
The intrinsic pathway critically contributes to activated platelet-promoted clotting in 
plasma (Walsh and Griffin, 1981) and arterial thrombus formation in mouse models 
(Renne et al., 2005a), suggesting that FXIIa is generated by platelets and that FXIIa-
driven fibrin formation proceeds on activated platelet surfaces (Colman, 2006; Furie 
and Furie, 2008). To assess whether polyP may present the “foreign surface”, that 
initiates FXII-driven fibrin formation on platelets, we determined whether phosphatase, 
which efficiently degrades polyP (Fig. 7A), inhibits procoagulant platelet activity. If 
polyP contributes to fibrin formation initiated by activated/procoagulant platelets, 
targeting polyP should interfere with clotting. Recalcification times in platelet-rich 
plasma (PRP) were determined in the absence or presence of phosphatase (10 U/ml), 
and platelets were either stimulated with calcium ionophore A23187 (5 µM, Fig. 14A) or 
Trap6 (30 µM, Fig. 14B) 10 min prior to CaCl2 addition. In the absence of phosphatase, 
platelet activation with A23187 and Trap6 reduced clotting times up to 3.2- and 2.9-
fold, respectively, as compared to untreated plasma (1st vs. 3rd column, Fig. 14A and 
B). Addition of phosphatase prior to recalcification almost completely abrogated the 
procoagulant activity conferred by stimulated platelets; clotting times in Ca2+-ionophore 
or Trap6 treated PRP were not significantly different from unstimulated PRP (A23187: 
365 ± 8 sec and Trap6: 411 ± 32 sec vs. 450 ± 2 sec, P>0.05, n=6 each, 4th column, 
Fig. 14A and B). Phosphatase did not alter the recalcification time in PRP without 
platelet activation (399 ± 13 sec, 2nd column in Fig. 14A and B). Consistent with our 
initial observation that clotting in A23187–stimulated murine PRP depends on FXII 
(Renne et al., 2005a), in vitro clotting in human FXII deficient PRP in response to either 
platelet agonist was severely impaired in the presence or absence of phosphatase 
(Fig. 14C and D). These findings demonstrate that activated/procoagulant platelets 
promote clot formation by polyP-stimulated intrinsic pathway of coagulation in vitro. 
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PolyP is procoagulant in plasma and in mouse models (Fig. 12 and 13). Platelets 
secrete polyP upon activation (Fig. 5) and targeting polyP interferes with clotting in vitro 
(Fig. 14A and B). To analyze polyP functions for pathological clotting driven by 
stimulated platelets in vivo, we established a model of lethal PE initiated by Trap6 
infusion (Fig. 14E). The thrombin receptor-activating peptide Trap6 activates platelets 
(Hamad et al., 2008) and initiates polyP secretion (Fig. 5), but has no direct effect on 
the plasma coagulation cascade and does not trigger fibrin formation in platelet-free 
plasma by another mechanism (not shown). Almost all (13/15) WT mice died within 5 
min after intravenous infusion of Trap6 (0.7 µg/g body weight) (Fig. 14E). In contrast, 
FXII-/- mice were largely protected from Trap6 induced lethal PE (13/15 survived; 
**P<0.01 vs. WT). Infusion of phosphatase (15 U/g body weight) prior to Trap6 
application protected WT mice from lethal PE and 13 out of 15 animals survived the 
challenge for >30 min. Lung histology from Trap6 treated mice confirmed PE 
(Fig. 14F). While the vast majority of vessels were obstructed in WT animals, virtually 
no thrombi were found in FXII-/- mice and in WT mice treated with phosphatase. 
Together these results show that polyP initiates plasma coagulation on procoagulant 
platelets in vivo. 
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Figure 14. Targeting polyP blocks platelet procoagulant activity in vitro and thrombosis in vivo. (A 
and B) Recalcification clotting times were determined in platelet-rich plasma stimulated with (A) A23187 
(5 µM) or (B) Trap6 (30 µM) in the presence (+) or absence (-) of phosphatase (10 U/ml; “Psp”). 
Reductions in clotting times are given relative to untreated plasma. Data are means ± SD, n=6. (C and D) 
The polyP-driven procoagulant activity of platelets depends on FXII. Recalcification clotting times were 
determined in platelet-rich plasma from a factor XII deficient individual (FXII levels <1 % as determined 
with the Siemens BSC-XP system) stimulated with A23187 (5 µM, C) or Trap6 (30 µM, D) in the presence 
(+) or absence (-) of phosphatase (10 U/ml, “Psp”). Reduction in clotting time is plotted relative to 
untreated plasma. Representative data are given from one of four tested FXII-deficient humans (means ± 
SD, n=5). (E) Mortality associated with i.v. injection of 0.7 µg/g body weight Trap6 in WT mice; FXII-/- mice; 
and WT mice injected i.v. with phosphatase (15 U/g body weight; “WT+Psp”) before Trap6 challenge. 13 of 
15 WT mice died within 10 min of challenge, whereas FXII-/- and phosphatase-treated WT mice were 
significantly protected from lethal pulmonary embolism induced by Trap6; 13/15 survived for >30 min each 
(FXII-/- and WT+Psp vs. WT, P<0.05, n=15 per genotype). (F) Targeting polyP interferes with pulmonary 
embolism in mice. Hematoxylin and eosin-stained lung sections of WT, FXII-/- mice, and phosphatase-
treated WT animals (“WT+Psp”) 30 min after Trap6 injection (0.7 µg/g body weight) (bar = 100 µm). 
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We further tested the importance of this concept for human disease states. 
Hermansky-Pudlak Syndrome (HPS) is a rare, complex hereditary disease (Gahl et al., 
1998), in which a bleeding diathesis results from platelet storage pool deficiency. PolyP 
is accumulated principally in dense granules secretory organelles, which are absent in 
HPS patients (Ruiz et al., 2004). We compared the ability of platelets isolated from 
these individuals to initiate coagulation to platelets from normal individuals (Fig. 15A). 
Platelets were Trap6-stimulated before addition to recalcified normal (platelet-free) 
plasma. Supplementing plasma with normal platelets resulted in a recalcification time 
of 280 sec with no additional shortening of the clotting time upon addition of exogenous 
polyP125 (10 µg/ml). Time to clot formation triggered by stimulated HPS platelets was 
longer (425 sec) and could be shortened to a ‘normal’ time of approximately 300 sec by 
addition of polyP. These results indicate that the concentration of polyP found in 
platelets is sufficient to trigger plasma coagulation, but that a reduction in the normal 
range of these concentrations, such as in HPS platelets, impairs the procoagulant 
potential of activated platelets.  
 
 
 
Cumulatively these findings support the concept that inorganic polyP is a new 
class of platelet-derived proinflammatory and procoagulant mediator, that exerts its 
effect by activation of the FXII-driven contact activation system. PolyP initiates fibrin 
formation on procoagulant platelets, linking primary to secondary hemostasis.  
Figure 15. (A) PolyP “rescues” defective fibrin formation 
in Hermansky-Pudlak Syndrome (HPS) patients. Human 
platelets were isolated from healthy blood donors (control) 
and from patients with HPS and stimulated for 10 min at 37°C 
with Trap6 (50 µM) and collagen (10 µg/ml). Recalcification 
clotting times in normal plasma on addition of either normal 
(control) or HPS platelets (HPS, 1.5 x107) in the absence 
(open bars) or presence (closed bars) of synthetic polyP125 
(10 µg/ml). The graph shown is representative of 3 different 
experiments performed on different HPS and normal 
individuals. This data resulted from a collaboration and were 
kindly provided by Dr. N. Mutch. 
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6 DISCUSSION 
Thrombosis may occur in the venous or arterial circulation, causing pulmonary 
embolism or myocardial infarction and stroke, the most common causes of death in the 
developed world (Mackman, 2008). Platelets play a pivotal role in vascular occlusive 
disease (Davi and Patrono, 2007; Furie and Furie, 2008; Ruggeri, 2002). These 
anucleate cells contribute to fibrin formation and inflammation leading to the concept of 
“procoagulant platelet activity”. This study demonstrates that the inorganic polymer, 
polyP, which is secreted upon platelet activation, is responsible for platelet-driven fibrin 
formation and vascular leakage. PolyP mediates its effects by activating the FXII-driven 
contact activation system. Targeting polyP attenuates procoagulant and 
proinflammatory platelet activity in vivo and may serve as a new strategy to interfere 
with platelet-driven thromboembolic and inflammatory diseases. PolyP links platelet 
plug formation (primary hemostasis) and fibrin generation (secondary hemostasis). 
PolyP functions are not limited to procoagulant disorders, but also contribute to 
platelet-driven capillary leakage, which is a hallmark of inflammatory reactions. 
In clinical aPTT clotting assays the anionic silicate kaolin is employed to activate 
FXII, which potently triggers FXII activation and induces fibrin formation by the intrinsic 
pathway in vitro (Cochrane and Griffin, 1982). Despite the importance of polyanion-
driven FXII activation for in vitro clotting assays, FXII activation is dispensable for 
hemostasis in vivo as FXII deficient individuals do not suffer from increased 
hemorrhage. However, using FXII null mice we demonstrated that FXII activity has an 
essential function for thrombus formation (Kleinschnitz et al., 2006; Renne et al., 
2005a). Severe deficiency in the clotting factor (<10 % plasma level) impaired the 
stability of the growing thrombus from the vessel wall without interfering with fibrin 
formation at wound sites. During pathological clotting FXII is likely to operate through 
the intrinsic pathway as factor XI-deficient mice are similarly protected from thrombus 
formation in FeCl3-induced arterial injury models (Renne et al., 2005a; Wang et al., 
2006).  
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Deficiency in FXII or FXI also impairs fibrin formation induced by ischemic brain injury 
(Kleinschnitz et al., 2006). The importance of the intrinsic pathway for thrombosis in 
humans remains less clear compared to animal models since individuals with severe 
deficiency of contact system proteases are rare (Gailani and Renne, 2007). However, 
factor XI may contribute to thrombosis in humans, since a congenital deficiency of this 
protein (<1 %) is associated with a reduced risk of ischemic stroke (Salomon et al., 
2008). The decisive role of the contact system for thrombosis is not restricted to 
intrinsic pathway proteases. HK-deficient mice have a normal hemostatic capacity, but 
impaired thrombus formation in the carotid artery (Merkulov et al., 2008). These in vivo 
studies are consistent with the critical role of the intrinsic pathway for fibrin formation by 
activated platelets in vitro (Johne et al., 2006; Walsh et al., 1976) and suggest that FXII 
activation proceeds on procoagulant platelet surfaces within the thrombus. In this study 
we have shown that polyP is released by activated platelets (Fig. 5), and that a 
phosphatase, which degrades polyP blocks fibrin formation promoted by procoagulant 
platelets in vitro and in vivo (Fig. 14). Circulating exopolyphosphatases in plasma may 
limit the activity of platelet-derived polyP (Schroder et al., 1999) and provide 
thromboprotection similar to infused exogenous phosphatase. 
PolyP is a “foreign” surface, that is not present under “normal” non-activated 
conditions. We failed to stimulate endothelial cells (EA.hy926, ECV304, HUVEC) to 
release polyP. Although these cells contain polyP, that could be liberated following cell 
injury (Fig. 5C and D), the polymer apparently does not significantly contribute to fibrin 
formation under these conditions, since FXII-deficient individuals do not bleed 
excessively. Either the endothelial polyP concentration is not sufficient to initiate the 
contact pathway, or yet unknown regulatory mechanisms interfere with polyanion-
driven FXII activation at the vessel wall. RNA, which activates FXII (Cochrane and 
Griffin, 1982) and is liberated from disintegrating cells, is prothrombotic, but does not 
contribute to hemostatic mechanisms (Kannemeier et al., 2007).  
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The mechanism by which polyP-initiated fibrin formation contributes to thrombosis is 
not entirely clear, but polyP appears to stabilize the growing thrombus distant from the 
vessel wall. In plasma polyP promotes fibrin formation (Smith et al., 2006) and 
improves the stability of the fibrin clot structure (Smith and Morrissey, 2008b). 
Thromboelastography assays (which measure mechanical stability of a clot in whole 
blood) indicate that FXII-driven coagulation contributes to clot stability and intravital 
microscopy showed rapid embolisations of the platelet aggregate in the vessels of FXII 
null mice (Renne et al., 2005a).  
FXII is activated by a variety of natural polyanions such as ellagic acid, 
nucleotides, sulfatides, misfolded proteins, and some types of collagen, or 
glycosaminoglycans (Cochrane and Griffin, 1982; Kannemeier et al., 2007; Maas et al., 
2008; May et al., 2008; Muller and Renne, 2008; van der Meijden et al., 2009). Some 
contact activators specifically trigger BK formation (Johne et al., 2006; Maas et al., 
2008; Schwartz, 2008), but do not initiate fibrin formation. Remarkably, patients with 
hereditary angioedema, who suffer from increased BK formation due to kallikrein-kinin 
system activity, do not have an increased thrombotic risk (Cugno et al., 1997; Zuraw, 
2008). The selective activation of the FXIIa-driven cascade suggests that delicate 
regulatory mechanisms of the contact system may exist, involving cell type-specific 
FXIIa effects (Renne et al., 2002a; Renne et al., 2005a) and FXIIa proteolysis products 
(Schmaier, 2008). 
Besides its importance for endogenous thrombus formation, synthetic polyP may 
be used as a hemostatic agent to reduce blood loss at sites of injury or during surgical 
interventions. Application of polyP has been shown to promote clot formation in plasma 
from hemophilia A and B patients (who are deficient in coagulation factor VIII or IX, 
respectively) (Smith and Morrissey, 2008a). In such plasmas procoagulant activities of 
polyP were additive to those of a recombinant form of active factor VII (rFVIIa), 
indicating that polyP-mediated fibrin formation is independent of the rFVIIa-driven 
extrinsic pathway.  
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In the present study we showed that polyP could “rescue” the prolonged clotting 
time of plasma containing platelets from HPS patients (Fig. 15). HPS is a disorder 
affecting endosome sorting and multiple platelet defects e.g. reduced ATP or serotonin 
storage and secretion result in bleeding syndromes of varying severity in effected 
patients (Nurden and Nurden, 2008), and whose platelets should therefore be unable 
to secrete polyP upon activation. As polyP-triggers FXIIa production (Fig. 7), which has 
the ability to efficiently activate FVII to FVIIa (Osterud and Rapaport, 1977), the 
polymer acts as a hemostatic adjuvant (Ong et al., 2008; Smith and Morrissey, 2008a). 
Indeed, FXIIa may bypass deficiency in factors VIII and IX by generating FVIIa in 
monkeys (Ton-That et al., 2000). 
Fibrin formation is initiated at a site of vessel injury when plasma factor VIIa binds 
to TF, a membrane protein found on cells underlying blood vessel endothelium. The 
importance of FVIIa/TF (the extrinsic pathway of coagulation) initiate thrombin and 
fibrin formation is highlighted by the fact that mice lacking factor VII or TF die 
perinatally in utero from severe hemorrhage. However the activity of the FVIIa/TF 
complexes at the vessel wall is likely limited by inhibitors such as tissue factor pathway 
inhibitor (TFPI) (Lu et al., 2004), and by accumulation of fibrin and platelets over the 
area of injury (Hathcock and Nemerson, 2004). TF has been recognized to be 
circulating blood and the blood borne TF may drive fibrin production apart from the 
vessel wall (Giesen et al., 1999). The concept that there may be functional significant 
amounts of tissue factor on platelets remains controversial (Panes et al., 2007). TF is 
expressed on procoagulant leucocyte-, monocyte- or vessel wall cell-derived 
microparticles, which become incorporated into a growing thrombus in a P-selectin–
dependent manner (Falati et al., 2003) and arterial thrombus formation is defective in 
mice expressing low levels of TF, although the relative contribution of vessel wall or 
blood cell–derived TF is not entirely clear (Chou et al., 2004; Day et al., 2005). As tiny 
amounts of active TF induce rapid clotting in plasma (Butenas and Mann, 2004), TF on 
microparticles may exist in a latent (encrypted) form that lacks coagulant activity. 
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Mechanism of TF encryption may involve lipid reorganization, secretion of TF 
containing granules, protein disulfide isomerase (PDI)-mediated dimerization 
(Reinhardt et al., 2008), and splicing of TF pre-mRNA (Schwertz et al., 2006). The 
relative contribution of TF- and FXII-driven fibrin formation for thrombosis is not know 
and may differ depending on the vascular bed, type of injury, and flow conditions. At 
least in human plasma, and in mouse PE models, blood borne TF is not sufficient to 
mediate fibrin formation on activated platelets in the absence of polyP (Fig. 14) 
indicating that polyP-driven FXII activation is an essential component for thrombus 
formation. 
FXIIa initiates several protease cascades in plasma, such as the kallikrein-kinin 
system, the intrinsic pathway of coagulation, and the complement and fibrinolytic 
systems (Gailani and Renne, 2007). In this study we have shown that polyP increases 
vascular leakage in mice by FXII-initiated BK formation (Fig. 9 and 10). Pre-formed 
FXIIa has been shown to induce leakage in skin microvessels in a BK-dependent 
manner in mice (Renne et al., 2005). Contact system-mediated kinin release is a 
critical component of Escherichia coli (E.coli) and Salmonella induced sepsis and 
septic shock (Herwald et al., 1998). It is not precisely known how these bacteria initiate 
BK-formation, but Salmonella (Kim et al., 2002) and E. coli (Rao et al., 1998) are 
known to contain high amounts of polyP. One can speculate that disintegrating bacteria 
may release the polymer, which could activate FXII and initiate BK-mediated leukocyte 
chemotaxis, pain sensations, and leakage (Leeb-Lundberg et al., 2005). 
Pharmacological inhibition of PK/FXIIa interferes with Salmonella induced pulmonary 
plasma leakage and blood cell infiltration in rats (Persson et al., 2000), again leading 
us to speculate that polyP may contribute to infectious disease. FXIIa can initiate the 
classical complement system, that generates C3a and C5a in host-defense reactions 
(Ghebrehiwet et al., 1981), and platelet activation triggers initiation and propagation of 
the complement system (Del Conde et al., 2005). PolyP released from activated 
platelets might therefore contribute to this response by generating FXIIa.  
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In addition to being anti-thrombotic phosphatase may serve as a potent anti-
inflammatory agent in reducing FXIIa-driven complement and BK effects with possible 
implications for acute and chronic inflammatory responses, such as atherosclerosis, 
rheumatoid arthritis, inflammatory bowel disease, and also in the progression of 
malignancies, or in immune responses to bacteria. 
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7 CONCLUDING REMARKS  
Beyond an eminent role in hemostasis and thrombosis at sites of injury, platelets have 
also prominent functions in inflammatory processes. Upon stimulation platelets release 
various kinds of proinflammatory and procoagulant mediators from their storage 
granules. In the present study, we identified polyP from human platelet dense granules 
as the long sought physiological surface for contact activation, culminating in 
inflammation as well as in blood coagulation. Platelets released this inorganic polymer 
after stimulation; polyP directly bound and activated coagulation factor XII. PolyP 
triggers in a FXII-dependent manner the activation of kininogen-processing kallikreins, 
and capillary leakage via release of bradykinin. Furthermore, polyP appeared to 
contribute to intrinsic blood coagulation. These findings establish inorganic polyP as a 
new class of proinflammatory and procoagulant substances that exert their activity by 
the activation of the FXII-driven contact phase system activation (Fig. 16).  
 
 
Figure 16. Function of platelet polyP in FXII-driven pathways. Activated platelets release polyP from 
their dense granules. This polyanion triggers on the one hand FXII-mediated thrombin formation via 
activation of the intrinsic pathway of coagulation and on the other hand edema formation via activation of 
the kallikrein-kinin system. 
 
Interrupting polyP-driven fibrin- and BK-generation interferes with thrombosis and 
edema formation in vivo. Platelet derived polyP may present a heretofore unrecognized 
target for intervention in FXIIa driven inflammatory and thromboembolic diseases. 
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